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Inflammation is a major risk factor for pancreatic ductal adenocarcinoma. When occurring
in the context of pancreatitis, mutations of KRAS accelerate tumor development. We discovered
that long after its complete resolution, a transient inflammatory event primes pancreatic epithelial
cells to subsequent transformation by oncogenic KRAS. Upon recovery from acute inflammation,
epithelial cells of the pancreas display an enduring adaptive response associated with sustained
transcriptional and epigenetic reprogramming. Such adaptation enables the prompt reactivation
of acinar-to-ductal metaplasia (ADM) upon subsequent inflammatory events, thus efficiently
limiting tissue damage via rapid decrease of zymogen production. We propose that since
activating mutations of KRAS maintain an irreversible ADM, they may be beneficial and under
strong positive selection in the context of recurrent pancreatitis.
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Chapter 1. Introduction
1.1 Inflammation
Mammalian body possesses a great ability of adaption to cope with different stimuli in
order to maintain tissue homeostasis. As a part of innate immunity, inflammation is a complex
biological process which the body utilizes against harmful stimuli caused by extrinsic factors
including pathogens, irradiation, trauma, and wounds, as well as intrinsic factors like
autoimmune attack and tissue damage due to ischemia and necrosis. Through inflammation, the
mammalian body can counteract potential insults, clean up damaged cells resulting from the
insults’ attack, and reestablish tissue integrity.
Inflammation works in a stepwise way to restore homeostasis.
Immune cell activation and recruitment: When target cells or tissues are being attacked, the
released danger signals (damage-associated molecular patterns, DAMPs) such as ECM
proteins, cytosolic proteins, DNA and RNA can initiate inflammation cascade by activating
nearby or resident immune cells, mainly dendritic cells and macrophages. Immune cells can also
be

directly

activated

by

pathogen-associated

molecular

patterns

(PAMPs)

like

lipopolysaccharide (LPS), which is expressed by invading pathogens. DAMPs and PAMPs serve
as ligands to bind to pattern-recognition receptors (PRRs) (e.g. Toll-like receptors (TLRs), NODlike receptors (NLRs) and RIG-I-like receptors (RLRs)) that are expressed on immune and
stromal cells. Activated PRRs then prime cells to initiate the inflammatory response (1). Activated
immune cells as well as endothelial cells then secrete pro-inflammatory mediators, such as IL1, TNFα, nitric oxide, histamine and different types of eicosanoids that act on smooth muscle
cells and endothelial cells to induce vasodilation and increase blood vessel permeability, which
facilitates the extravasation of circulating immune cells (2). Meanwhile, cytokines and
chemokines secreted by activated immune cells can up-regulate cell adhesion molecule
expression on endothelial cells to increase their binding affinity toward circulating immune cells
(2) as well as create a chemotaxis gradient to guide the further recruitment of immune cells to
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the inflamed tissue for a more effective and stronger immune response. Among the circulating
immune cells, neutrophils are the first to be recruited upon initiation of inflammation, followed by
monocytes/macrophages. Alongside immune cells, vascular remodeling also brings in plasma
proteins, such as complement, enzymes, and antibodies to potentiate the inflammatory response.
Inflammation can also activate coagulation (3). Indeed, in injured tissues, endothelium damage
and blood exposure activate platelets, Factor-VII, fibrin, and thrombin for a coagulation cascade
that prevents further blood loss and infection. The activation of the inflammation cascade can
further promote coagulation through increasing the number and activity of platelets as well as
other coagulation factors. Through positive feedback, platelets can secrete pro-inflammatory
cytokines like IL-1, CD40 ligand, and chemokines to enhance inflammatory responses (4).
Phenotypic alert: Due to vasodilation and increased vascular permeability, increased blood flow
leads to redness and increased heat in inflamed tissues. Moreover, the movement of plasma
fluid results in edema and tissue swelling. The release of inflammatory mediators such as
bradykinin and histamine can sensitize nociceptors (pain receptors) to generate pain. These
classical signs of inflammation (calor, dolor, rubor and tumor), as reported by Aulus Cornelius
Celsus in the first century A.D., alert body to ongoing injuries or insults in order to avoid further
exposure and reduce potential damages.
Insult elimination: Invading pathogens can be eliminated through phagocytosis via recruited
neutrophils and antigen-presenting cells (APCs) like macrophages and dendritic cells. APCs can
further digest engulfed materials and present exogenous antigens on the MHC-II complex to
bridge innate and adaptive immune responses. Lysozymes, complements and antibodies
contained in plasma fluid can also exert anti-microbial function through various mechanisms.
Other insults may be diluted and removed by increased blood flow (5).
Cell debris clean up: Cell debris resulting from necrosis or apoptosis can be eliminated by
phagocyte-mediated phagocytosis (6). DAMPs released from necrotic cells can further activate
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immune cells and secrete more inflammatory cytokines to maintain the inflammatory process till
the insults are resolved.
Inflammation resolution and tissue repair: Once the insults have been removed and inflamed
tissue enters the resolution phase, several mechanisms occur to ensure the clearance of
inflammation effectors, including down-regulation of pro-inflammatory signaling pathways,
scavenging of pro-inflammatory mediators, and induction of neutrophil apoptosis followed by
efferocytosis. At the moment, macrophages start to undergo class switch from pro-inflammatory
(M1) to anti-inflammatory (resolution-phase macrophages or M2) macrophages and this change
in polarization is essential for tissue repair. Pro-inflammatory macrophages and other immune
cells secrete regenerative cytokines such as IL-6, TNF, IL-13, and IL-22 to activate the
transcriptional network in adult stem cells or normal differentiated cells for proliferation,
differentiation, survival, and motility, which contributes to tissue regeneration. Resolution-phase
macrophages, on the other hand, secrete anti-inflammatory cytokines such as TGF-β and IL-10
to cease more inflammation and reach the balance state for effective tissue regeneration.
Resolution-phase macrophages also cooperate with other stromal cells like myofibroblasts to
promote re-epithelialization, angiogenesis, and tissue remodeling (7-12).
Numerous signaling pathways are involved in inflammation. Among these, activation of
the NF-κB pathway, TBK1-IRF3 pathway, MAPK pathway, inflammasome pathway, and JAKSTAT pathway are responsible for the majority of inflammatory responses (13).
NF-κB pathway: The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
pathway was first described by David Baltimore’s group in 1968 as a B-cell specific transcription
factor (14). In the past decades, a large body of observations reported that the NF-κB family
plays as a pivotal regulator in many cellular responses, including inflammation, cell proliferation,
cell death and survival, and the adaptive immune response. The NF-κB family consists of 5
family members: NF-κB1 (p105), NF-κB2 (p100), RelA (p65), RelB, and c-Rel, which can form
various homodimers and heterodimers in different contexts (15). NF-κB signaling comprises of
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the classical/canonical NF-κB pathway and the alternative/uncanonical pathway (16). The
classical pathway is activated by the engagement of PAMPs, DAMPs, and pro-inflammatory
cytokines through a variety of specific receptors including PRRs, the TNF receptor, and the IL-1
receptor. The ligand-receptor interaction in turn activates the IKK complex (IKKα, IKKβ and IKKγ)
followed by phosphorylation and ubiquitination of NF-κB inhibitor IκBα. Proteasome-mediated
degradation of IκBα frees NF-κB to form the p50/p65 heterodimer, allowing the nuclear
translocation of the complex and the regulation of target gene expression. The classical NF-κB
pathway is rapid and transient due to no requirement of NF-κB protein synthesis. The output of
the activation of the classical NF-κB pathway includes the production of pro-inflammatory
cytokines (ex. IL-1β, IL-6 and TNF), chemokines (ex. RANTES, IL-8 and MCP1), growth factor
(ex. GM-CSF), cell-adhesion molecules (ex. P-selectin, E-selectin and ICAM-1), proinflammatory enzymes (ex. iNOS and COX2), anti-apoptotic proteins (ex. BCL‐xL and BCL‐2),
and matrix metalloproteinase (ex. MMP9), which are responsible for the vast majority of
inflammatory responses (13, 15). The alternative pathway, on the other hand, is activated by a
panel of cytokines belonging to the TNF family, including lymphotoxin (LT), receptor activator of
NF‐κB ligand (RANKL), and CD40 ligand (CD40L) through the activation of IKKα homodimer.
The functional NF-κB protein complex in the alternative pathway is p52/RELB, which regulates
gene expression involved in the development and maintenance of secondary lymphoid organs
(15).
TBK1-IRF3 pathway: Beside NF-κB pathway, the TANK binding kinase 1 (TBK1)-interferon
regulatory factor 3 (IRF3) pathway is another common pathway activated by the engagement of
specific receptors like TLRs and RLRs through different adaptor proteins (13). Cytosolic doublestrand DNA induced STING-cGAS signaling can also contribute to the activation of the TBK1IRF3 pathway (17). When TBK1 being activated, it can phosphorylate its downstream target
transcription factor IRF-3. Phosphorylated IRF-3 then undergoes dimerization and enters the
nucleus to promote the expression of type-I interferons (interferon-α and β). Type-I interferons

4

can bind to IFNα receptor 1 (IFNAR1) and IFNAR2 in an autocrine or paracrine-dependent
manner. The engagement of IFNAR1-IFNAR2 complex leads to the activation of the JAK-STAT3
pathway and drives the expression of interferon-stimulated genes (ISGs) for anti-viral functions
(18).
MAPK pathway: Analogous to the activation of NF‐κB pathway and TBK1-IRF3 pathway, the
engagement of PRRs and the TNF receptor can activate the mitogen-activated protein kinase
(MAPK) pathway during inflammation (13). MAPK cascades consist of three major branches:
classical MAPK (ERK), C-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK),
and p38 kinase, which are known for regulating cell proliferation, differentiation, development,
and death (19). JNK and p38 kinase are activated in a transforming growth factor-beta-activated
kinase 1 (TAK1)-dependent manner (20). JNK activation leads to the formation of AP-1
transcription factors (21), whereas p38 kinase activation in turn activates transcription factors
CREB and c/EBPβ (13). Phosphorylated IKKβ in the IKK complex activates not only the NF‐κB
pathway but also ERK, which in turn activates transcription factors like Elk1 and ATF2 (22, 23).
Transcription factors activated by the MAPK pathway can then cooperate with NF-κB to regulate
the expression of numerous pro-inflammatory genes (15).
Inflammasome pathway: IL-1β is one of the major pro-inflammatory cytokines produced and
secreted during inflammation. The activation of the NF‐κB pathway drives IL-1β gene expression
in the way of pro-IL-1β production; however, the maturation and secretion of IL-1β requires the
assistance of inflammasomes. Inflammasomes are multimeric protein complexes named by
different scaffold or sensor proteins, such as NLRP3, AIM2, and NLRC4 (24). In response to
DAMPs or PAMPs engagement, scaffold proteins interact with the adaptor protein ASC and
recruit pro-caspase-1. Oligomerization of pro-caspase-1 undergoes autoproteolytic cleavage
and generate active caspase-1, which in turn converts pro-IL-1β into mature form to exert its
pro-inflammatory function (25).
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JAK-STAT pathway: The Janus kinases (JAK)-signal transducer and activator of transcription
proteins (STAT) pathway is mainly activated by cytokine engagements and involved in the
inflammatory response. Upon binding to cytokine ligands, cytokine receptors dimerize and
activate associated JAKs followed by the phosphorylation of different STAT proteins.
Phosphorylated STAT proteins then translocate into nucleus and act as transcription factors to
regulate their downstream gene expression. As one of the main targets of the NF‐κB pathway,
the pro-inflammatory cytokine IL-6 stimulates the expression of plasma protein like acute phase
proteins through the JAK-STAT3 pathway and induce fever, chemotaxis, opsonization, and
coagulation during inflammation (26).
Inflammation is usually resolved after the removal of the insults followed by tissue repair
and homeostasis restoration. Since it is rapid and only last for few days, this type of inflammation
is also termed acute inflammation and is beneficial to human body. If the insults are persistent
and hard to eliminate, however, the inflammatory phase will be maintained and amplified by
positive-feedback loops and generate prolonged inflammation, termed chronic inflammation (27)
(Figure 1). At the phase of chronic inflammation, other types of immune cells including
lymphocytes and plasma cells are recruited and mediate both innate and adaptive immunity (28).
Chronic inflammation can last many years and can be harmful as it can eventually lead to tissue
remodeling and organ failures.
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Figure 1. Acute versus chronic inflammation. Inflammation can be directed to either acute
inflammation with hemostasis restoration in the end or to chronic inflammation due to persistent
insults. Excessive/prolonged inflammation eventually causes chronic inflammatory disease.

1.2 Inflammation acts as a double-edged sword
As the first line of defense, the physiological role of inflammation is to detect and eliminate
threats to the body. Chronic inflammation, like acute inflammation, recruits inflammatory cells to
produce different cytokines, enzymes, and reactive oxygen species (ROS). While these
inflammatory mediators can help with the elimination of the insults, prolonged inflammation
damages host tissues and creates conditions that worsen disease. In other words, inflammation
when not finely tuned, can act like a double-edged sword.
One example of excessive acute inflammation-caused disorders is sepsis or systemic
inflammatory response syndrome (SIRS). Sepsis is a complicated syndrome that contributes to
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the highest mortality in hospitalized patients due to multiple organ dysfunction (29). Sepsis
mainly results from an extreme inflammatory response toward systemic pathogen infection,
although noninfectious causes can also lead to sepsis (30). The onset of inflammation is induced
by PAMP and DAMP recognition via PRRs and the subsequent response exerts its function to
target invading pathogens. For unknown reasons that may include genetic and environmental
factors as well as pathogen load and virulence, inflammation may become dysregulated and lifethreating (31). Indeed, an overactivated inflammatory response can trigger organ dysfunction by
up-regulating procoagulant pathways and enhancing the formation of blood clots. Excessive
blood clots then lead to microvascular occlusion and impair tissue perfusion, which ultimately
cause organ failure (32). The overproduction of cytokines, or the cytokine storm during sepsis,
can also cause organ failure due to the release of ROS and enzymes that directly damage cells
and tissues (33). Increased ROS could also damage mitochondria disrupting TCA cycle and the
electron transport chain, which eventually suppresses ATP production and impairs bioenergetics
(30).
Chronic inflammation can result in tissue remodeling. Asthma is a chronic inflammatory
disease that occurs in airways and is characterized by airway obstruction. Symptoms of asthma
include cough, wheeze, shortness of breath, and chest tightness. Two main categories of asthma
have been established as allergic and non-allergic asthma. In recent years, more asthma
endotypes have been identified based on their pathophysiological features (34). Allergic asthma
is usually induced in childhood, when the body encounters potential allergens like pollen or
house dust mites, and persists into adulthood. Adulthood exposure to allergens could also
induce allergic asthma. Two types of cells are involved in the initiation of airway chronic
inflammation when exposed to allergens: airway resident dendritic cells and epithelial cells.
Tissue resident dendritic cells get activated through allergen recognition and produce
inflammatory mediators to induce inflammation. Dendritic cells can also engulf allergens and
present them on the MHC-II complex to prime helper T cells. Epithelial cells, on the other hand,
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express pattern-recognition receptors (e.g. TLRs, NLRs, and RLRs) to bind to allergens and
induce cell activation and cytokine production. Epithelial-derived cytokines like IL-33, TSLP, IL1α, or GM-CSF can engage antigen-presenting dendritic cells to promote naïve helper T cells to
differentiate into T-helper 2 cells (Th2 cells) (34). Th2 cells can then produce several cytokines,
including IL-5, that can activate recruited eosinophils in airways to cause tissue eosinophilia (35),
which is one of the hallmark features of asthma. Other immune cells, like B cells and mast cells,
also contribute to chronic inflammation. Persistent inflammation caused by eosinophil
degranulation leads to lung cell damage. Moreover, eosinophils can secrete fibrogenic factors
to induce airway remodeling, which is manifested by smooth muscle thickness, subepithelial
fibrosis, and mucus overproduction, and eventually leads to airway obstruction (34, 36).
The induction of chronic inflammation can be independent of pathogens or allergens.
Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks body
joints, resulting in chronic inflammation and loss of function of joints as well as other systemic
complications. The cause of RA is not well-established, but both genetic and environmental
factors have been reported to be involved in RA development. Recently, two intriguing models
that combine clinical observation and genetic analysis have been proposed (37). One of them
suggests that genetic risk alleles, such as HLA-DRB1, can increase the efficiency of antigen
presentation to T cells to induce the adaptive immune response and autoantibodies production
(38, 39). The generation of autoantibodies can then target self-antigens to form immune
complexes and activate macrophages. Released cytokines and chemokines by macrophages
can further lead to metabolic alteration, stromal activation, and chronic inflammation to cause
tissue damage. The other model suggests that the activation of the innate immune response
releases cytokines and chemokines, which subsequently activates stromal cells and causes
epigenetic changes. The interaction between immune cells and stromal cells enhances the
positive-feedback loops of inflammation to damage tissues. Autoimmune response may act as
the consequence of overactive inflammation and further promote RA disease progression.
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Inflammation is a key player in cancer development. Chronic inflammation is correlated
with a high risk of cancer, and the vast majority of cancers, if not all, are associated with chronic
inflammation. Besides germline mutation-caused inflammation, most chronic inflammation cases
are caused by environmental factors, including the use of tobacco, air pollutants, alcohol, dietary
factors, obesity, and chronic infection (40).
Pathogen infection has been reported to be involved in up to 20% of all cancer cases
(41). One example is the infection with gram-negative bacteria Helicobacter pylori, which is
known as the highest risk factor for gastric cancer development (42). The virulent factors of
Helicobacter pylori activates multiple kinase-related pathways and the β-catenin pathway to
promote cell proliferation, migration, and tumorigenesis (42). Further, infection of Helicobacter
pylori can induce the up-regulation of pro-inflammatory cytokines such as IL-1β and proinflammatory enzyme COX-2 in gastric tissues. Increased IL-1β leads to hypochlorhydria and
atrophic gastritis, while COX-2 activation produces chemokines and cytokines to sustain
inflammation. Helicobacter pylori infection can also cause oxidative stress and loss of cell
polarity, which, together with the activation of oncogenic pathways and inflammation, promote
gastric tumorigenesis (43). Another example of tumorigenesis involving pathogen-induced
inflammation is hepatitis and hepatocellular carcinoma (HCC). Chronic viral hepatitis caused by
the hepatitis B virus (HBV) or hepatitis C virus (HCV) is the most common risk factor for HCC
(44). During chronic hepatitis, NF-kB pathway is activated through the production and
engagement of pro-inflammatory cytokines like TNF and IL-1. The JAK-STAT3 pathway can also
be activated by elevated IL-6 during chronic inflammation. The activation of NF-κB and STAT3
pathways leads to the expression of pro-survival genes and promotes cancer cell survival,
proliferation, and epithelial-to-mesenchymal transition (EMT). These activated pathways
ultimately enhance HCC development (15).
Pancreatitis or pancreatic inflammation, like viral hepatitis and atrophic gastritis, is a risk
factor for pancreatic cancer. The pancreas is a specialized organ that produces digestive
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enzymes for food digestion. Digestive enzymes are produced in the form of zymogens (inactive
form of enzyme) in the pancreas and become active after being secreted and transported to the
small intestine. In patients with an history of gallstones or alcohol abuse, obstructed enzyme
secretion may result in the activation of intra-pancreatic zymogens, which leads to autodigestive
injury and acute inflammation (45). Chronic pancreatitis can progress from acute pancreatitis
(46). Although it has a lower incidence compared to acute pancreatitis, chronic pancreatitis can
increase the relative risk of pancreatic cancer up to 13-fold (47), Indeed, about 5% of patients
with chronic pancreatitis develop pancreatic cancer (48). Further, 10% to 40% of chronic
pancreatitis patients possess the oncogenic KRAS mutation, which is responsible for pancreatic
cancer initiation and progression. Moreover, KRAS mutations can be detected in inflamed
tissues adjacent to pancreatic tumors, suggesting that inflamed pancreatic tissues with mutated
KRAS may be more likely to develop into tumors (48). It’s well established in animal models that
chronic pancreatitis is essential for oncogenic KRAS-induced pancreatic cancer progression in
adult mice (49). Pro-inflammatory cytokines like TNF, IL-1, and IL-6 produced during chronic
inflammation have been reported to activate the NF-κB and STAT3 pathways, which accelerate
pancreatic cancer progression. Additionally, production of these pro-inflammatory cytokines
correlate with poor prognosis in pancreatic cancer patients (15).
Taken together, inflammation is critical for defending the body, tissue repair, and the
restoration of homeostasis. The dysregulation of inflammation, however, can induce adverse
effects that can either directly cause disease or promote the progression of other diseases.

1.3 Cell adaptation and metaplasia
Inflammation is a tissue response mediated by immune cells and stromal cells to cope
with insults. Beside the systematic body response, local cells or tissues have developed their
own ways to deal with insults or stimuli by changing cell morphology, number, metabolism, or
identity. This process is, overall, termed cellular adaptation. Depending on the type of stimuli,
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the target cell type, and the duration of the stimuli, cellular adaptations can be either
physiological or pathological. Several common cellular adaptations have been reported,
including atrophy, hypertrophy, hyperplasia, dysplasia, and metaplasia (50).
Atrophy describes the state of decreasing cell size, which can in turn affect the size of the
whole tissue or organ. Stressors such as lack of blood supply (nutrient deprivation), loss of
endocrine stimulation, as well as denervation and compression can cause a net loss of proteins
and organelles, all of which could lead to atrophy (50, 51). In response to these stressors, cells
can up-regulate different pathways such as autophagy or the ubiquitin–proteasome system to
accelerate protein breakdown and organelle clearance to better adapt to environmental changes
(51).
Hypertrophy, which is opposite to atrophy, is the increase in cell size. Hypertrophy usually
happens as a result of increased workload, which manifests as enlarged organelles and protein
accumulation. This eventually leads to larger tissues or organs (50). Cells that undergo
hypertrophy are postmitotic, meaning that they have lost the ability to proliferate. However,
cellular hypertrophy may provide an alternative mechanism to compensate for cell loss in
response to different stimuli for maintaining homeostasis in postmitotic tissues (52).
Similar to the phenotype of hypertrophy, hyperplasia also leads to tissue or organ
enlargement, but this enlargement is due to an increase in cell number or proliferation rather
than size. Different stimuli can cause hyperplasia, including chronic inflammation, hormonal
stimulation, and tissue damage. Tissues with physiological hyperplasia usually return to the
normal state when stimuli are removed, and cells resulting from hyperplasia appear normal
morphologically and functionally. However, excessive or persistent stimuli can lead to
pathological hyperplasia, and some cells may become precancerous and progress to neoplasia
(50).
Dysplasia refers to the abnormal growth of cells within a tissue or organ that can happen
during developmental or adult stages. Various factors, such as virus infection, mutation, or
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environmental factors, can cause dysplasia in different tissues or organs. Dysplasia can be
classified into different grades, and is usually diagnosed by abnormal cell morphology, atypical
nuclear size and chromatin architecture, and increased cell mitosis (50). Dysplasia is not cancer,
but low-grade dysplasia is thought to be premalignant or acts as a precursor of neoplasia, and
may progress to cancer. High-grade dysplasia, however, is close or equal to carcinoma in situ
(CIS), and represents fully transformed cells with no apparent invasion (53).
Atrophy, hypertrophy, hyperplasia, and dysplasia describe the functional changes of the
original cell in efforts to adapt to intrinsic or extrinsic stimuli. Metaplasia, on the other hand, is
the change of one cell type to a cell type that doesn’t normally exist in a specific tissue (54).
Similar to metaplasia, transdifferentiation is a process defined as when a differentiated cell type
is converted to another cell type (55). While studies have tried to separate metaplasia and
transdifferentiation conceptually, well-established distinctions between the two phenomena are
still missing. Originally, metaplasia was viewed as a wider class of cell-type conversion that
contained transdifferentiation (55), but was later re-defined as a converting process between
different tissues; by contrast, transdifferentiation refers to the conversion between differentiated
cell types (56). However, some groups define metaplasia as a conversion process at the cellular
level, a definition which blurs the difference between metaplasia and transdifferentiation (54).
Despite its ambiguous definition, metaplasia represents a unique type of cell adaptation in
response to environmental stimuli and is related to the change of cell identity. Moreover, tissue
metaplasia often acts as precursor lesions for neoplasia (54, 57). Different types of tissue
metaplasia have been identified, including squamous metaplasia, intestinal metaplasia, and
acinar-to-ductal metaplasia (54). One example of squamous metaplasia is cervical metaplasia,
during which the cervical columnar epithelium is replaced with squamous epithelium in response
to an acidic environment. Although the exact cells of origin of cervical metaplasia are not well
understood, cervical columnar epithelial cells possess the ability to transform to stratified
squamous epithelial cells through proliferation and differentiation. The region of cervical
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metaplasia is the most vulnerable site for HPV infection, which can cause cervical dysplasia and
neoplasia (58). Barrett’s esophagus is a classic example of intestinal metaplasia in which
squamous epithelial cells convert to goblet cells and columnar cells in response to acid reflux,
inflammation, or other stimuli. Goblet cells are mucin-producing cells that can protect cells from
further stimulation, demonstrating a cell adaptation mechanism. Patients with Barrett’s
esophagus are at risk for developing dysplasia and progressing to esophageal adenocarcinoma
(54).
Pancreatic acinar-to-ductal metaplasia (ADM) is unique in terms of cells of origin and its
phenotype. The term “ductal metaplasia” was first mentioned by Ismail Parsa and colleagues in
1985, and describes the phenomenon in which pancreatic acinar cells undergo degeneration,
lose zymogen granules, and form duct-like structures. In the manuscript, the authors also
reported that human ductal metaplasia was associated with clinical pancreatic carcinoma (59).
The first in vivo model of ADM was demonstrated by transgenic mice that overexpressed TGFα (60). TGF-α is a member of the epidermal growth factor (EGF) family of proteins, and it can
act as a ligand to activate EGF receptor (EGFR) that is essential for cell survival, proliferation,
and differentiation. When TGF-α was placed under an elastase promoter, an acinar cell specific
marker, it caused widely separated acini and multiple duct-like structures that resembled the
phenotype of ductal metaplasia. Although increasing studies on ADM indicate that the transition
from acinar to ductal-like cells is not canonical metaplasia but, rather, transdifferentiation, the
term ADM is still widely used to describe the phenomenon (61). In the past decade, studies on
ADM have given rise to several characteristics of ADM: 1) loss of acinar cell identity markers,
such as PTF1a (also known as p48), MIST1, and GATA6 (62), 2) loss of the original function of
acinar cells (e.g. the reduced expression of zymogens, such as amylase and elastase), and 3)
upregulation of ductal cell markers, such as SOX9 and cytokeratin 19 (62). In addition to
molecular characteristics, histological analyses of ADM feature visible hollowed spaces among
acini, which indicate loss of normal apical granularity and polarization. Further, the cells
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surrounding the hollowed spaces will transition from cuboidal to columnar (63), demonstrating a
gain of duct-like structures. Several signaling pathways have been reported to participate in the
process of ADM, and the convergence of these pathways to RAS signaling suggests that RAS
signaling is the most important driver for ADM (64). Under normal conditions, the activation level
of RAS signaling is not sufficient to induce ADM. However, stimuli that can increase RAS
activation level to a certain threshold may be able to promote ADM formation. ADM-induced
stimuli can be divided into genetic and non-genetic events based on their origin (65). Genetic
events are intrinsic stimuli induced by gene alteration, such as oncogenic activation of KRAS by
KRAS mutation at codon 12, which is responsible for the aberrant RAS signaling in most
pancreatic intraductal neoplasia (PanIN) and PDAC. Non-genetic events, on the other hand, are
extrinsic, such as injury or damage-induced inflammation that can activate RAS signaling. In
addition to RAS signaling, other signaling pathways also participate in the process of ADM,
including the PI3K-AKT, JAK-STAT and Notch pathways (61). Pancreatitis is the most common
non-genetic stimulus to cause ADM. Specifically, when pancreatitis is resolved, ADM will be
reversed, with ductal-like acinar cells returning to the state of normal acinar cells. However, if
genetic stimuli occur to acinar cells, the aberrant RAS signaling will be maintained and prevent
the reversal of ADM. This, ultimately, promotes progression to pancreatic cancer.

1.4 Cellular plasticity and epigenetic reprogramming
Different types of cell adaptions, especially metaplasia, demonstrate that even at the state
of terminal differentiation, cells still possess the ability to change in response to stimuli, a
property known as cellular plasticity (57). Despite the fact that cells within an organism share the
same genome, the tight regulation of tissue-specific transcriptomic networks in cells enable cell
differentiation and variation in function and cell type (66). Transcriptional regulation depends on
numerous factors, including genetic or nongenetic initiating signals/stimuli, signal transduction,
and chromatin accessibility. Genetic stimuli can be constitutive gene activation or gene silencing
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that leads to the activation or deactivation, respectively, of downstream signal transduction.
Mutations in chromatin regulator genes could also contribute to chromatin changes. Nongenetic
stimuli, on the other hand, can be growth factors, metabolism, cell stress, aging, and
inflammation. Signal transduction downstream of initiating signals/stimuli ensures the activation
and nuclear translocation of transcription factors or other effectors responsible for transcription
initiation. Chromatin accessibility acts as the rate-limiting step of transcriptional regulation due
to its ability to enable the recruitment of enzymes like RNA polymerase, activated transcription
factors, and other co-factors to initiate transcription in euchromatic regions. Chromatin
accessibility is determined by chromatin structure, which is regulated by transcription factors,
chromatin remodelers, insulators and histone/DNA modifications (67, 68). Histone acetylation
H3K27ac and trimethylation H3K4me3 mark highly accessible chromatin regions, or active
chromatin, whereas DNA hypermethylation and the recruitment of chromatin repressors leads
to repressive chromatin restricting the accessibility of transcription machinery. Terminaldifferentiated cells usually have tightly regulated chromatin accessible regions to ensure the
expression of tissue-specific genes. By contrast, stem cells or progenitor cells possess
hyperdynamic chromatin and relatively higher chromatin accessibility, namely high cellular
plasticity, to enable the differentiation into different cell types in response to environmental cues
(66). However, when environmental stimuli are strong enough to induce epigenetic changes, or
epigenetic reprogramming that extend chromatin accessibility to other cell/tissue-specific
regions, differentiated cells may gain the ability to convert their cell identity to other cell types,
which can then lead to metaplasia or transdifferetiation. Cells undergoing metaplasia or
transdifferentiation may be fixed into the new differentiation state or re-differentiate back to the
original state, depending on the nature, frequency, duration, and intensity of the stimulation (57).
In spite of metasplasia and transdifferention, epigenetic reprogramming plays a pivotal
role in tumor progression. Tumor cells are not normal stem cells, but both share the feature of
high cellular plasticity. Oncogene-induced reprogramming makes tumor cells more plastic and
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adaptable in response to environmental stimuli while in a deregulated manner. The chromatin
state of tumor cells can be either restrictive or permissive. Restrictive chromatin results from the
action of the Polycomb-family repressor or other regulatory proteins, and can inactivate
apoptosis or differentiation programs, which in turn leads to the deregulated accumulation of
tumor cells (66). Permissive chromatin, on the other hand, can be induced by oncogenic
mutations and environmental insults. For example, oncogenic Kras mutations can fix and
maintain pancreatitis-induced chromatin changes and activate neoplasia-specific activated
programs, which contribute to the progression of pancreatic cancer (69).
Epigenetic reprogramming does not always lead to a change of cell identity. Instead,
within the original cell fate, it can confer physiological advantages when coping with
environmental insults. Skin epithelial stem cells (EpSCs) can be epigenetically reprogrammed
after acute inflammation to increase chromatin accessibility of inflammation-induced stress
response genes while still maintaining its cell identity. The increased chromatin accessibility, or
inflammatory memory, allows EpSCs to rapidly respond to the secondary challenges of
stimulation via up-regulation of inflammation-induced programs, including the AIM2
inflammasome and its downstream effectors caspase-1 and IL-1β. The rapid up-regulation of
the AIM2-IL1β pathway can then enhance the rate of skin wound repair, which results in faster
tissue recovery (70).

1.5 Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic
cancer, and its high mortality rate makes it one of the deadliest cancer types in the world (71,
72). Due to the lack of promising biomarkers for early screening tests and no obvious symptoms
at early stages, patients with PDAC are usually diagnosed at an advanced stage.
Fluoropyrimidine (i.e. gemcitabine) and Nab-paclitaxel-based chemotherapy are standard
treatments for advanced PDAC. However, the emergence of drug resistance and low response
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rates result in an overall 5-year survival rate of less than 10% (71, 72). Therefore, it’s imperative
to understand the initiation process of PDAC, which can provide more insights into the early
detection and diagnosis of PDAC.
Pancreatic structure
The pancreas can be functionally divided into endocrine and exocrine compartments. The
endocrine pancreas consists of primarily alpha and beta cells that are responsible for producing,
respectively, glucagon and insulin, which are needed to regulate blood glucose levels. Alpha,
beta, and other specialized cell types in the endocrine pancreas are organized into clusters
called Islets of Langerhans (73). The exocrine system is made up of acinar cells and ductal cells.
An acinus is a functional unit composed of acinar cells, which synthesizes and excretes digestive
zymogens into the gastrointestinal tract through the duct network. The exocrine system
comprises 80% of the tissue mass of the whole pancreas (73). In other words, the majority of
the pancreas is constituted by acinar cells.
Morphological characteristics of PDAC
The nomenclature of PDAC derived from its histological similarity to ductal cells (74).
PDAC primarily displays patterns of duct-like structures and abortive glands as well as exhibits
different degrees of cellular abnormalities, such as nuclear irregularities and enlarged nuclei (75).
PDAC presents with a high potential to spread out to distant regions. Even the smallest lesions
possess the ability to perform perineural and lympho-vascular invasion (73). Three types of
precursor lesions have been identified for PDAC: pancreatic intraepithelial neoplasia (PanIN),
mucinouscystic neoplasm (MCN), and intraductal papillary mucinous neoplasm (IPMN) (76).
Compared to MCM and IPMN, PanIN is the most common and extensively studied one that is
viewed as the canonical precursor lesion of PDAC (73). Previously, PanINs were graded in three
stages— PanIN-1, PanIN-2, and PanIN-3 –that reflects a progressive model from low-grade
(PanIN-1) to high-grade (PanIN-3). PanIN-1 is characterized by flat (PanIN-1A) or papillary
(PanIN-1B) epithelial lesions with tall columnar cells and basally located nuclei. PanIN-2 lesions
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exhibit increased nuclear abnormalities compared to PanIN-1, including loss of polarity, nuclear
crowding, pseudo-stratification, and hyperchromatism. PanIN-3 lesions are usually papillary,
with small clusters of epithelial cells budding off into the ductal lumen (75, 77, 78). Since 2015,
the classification for PanIN has been revised to low-grade PanIN (former PanIN-1A, PanIN-1B
and PanIN-2) and high grade-PanIN (PanIN-3) (79). The high-grade PanINs possess a high risk
of progressing into PDAC. The PanIN-to-PDAC progression model is supported by studies
revealing that high-grade PanINs and PDAC share many somatic alterations (80, 81).
Molecular characteristics of PDAC
Numerous cancer-related mutations have been reported in PDAC. Large-scale genomic
sequencing suggests that these somatic alterations accumulate in a stepwise manner during
PDAC progression. However, the existence of chromothripsis, a catastrophic genomic event that
leads to genetic alterations in a single cell division, enables the possibility that alternative models
of progression ,such as punctuated evolution, may exist in PDAC (80, 81). Four major recurrent
gene mutations have been identified in PDAC: the oncogene KRAS and the tumor suppressors
CDKN2A, TP53, and SMAD4 (80, 81). KRAS activating mutations are the most common
oncogenic mutations found in PDAC; moreover, more than 99% of low-grade PanIN possess
KRAS mutation, making it presumably the initiating event in PDAC progression (82). The tumor
suppressor gene CDKN2A encodes p16INK4A and p19ARF, which act as G1/S phase cell cycle
inhibitor and a stabilizer of p53, respectively. CDKN2A inactivating mutations are present in lowgrade PanIN and the majority of PDAC (>90%) (83). The transcription factor p53 regulates cell
cycle arrest, DNA repair, and apoptosis in response to DNA damage or cellular stress.
Inactivating mutations in TP53 are found in high-grade PanIN and up to 85% of PDAC (81, 84).
As the binding partner of SMAD2 and SMAD3, SMAD4 mediates the transforming growth factorβ (TGFβ) canonical signaling pathway to regulate cellular growth, differentiation, and
maintenance of tissue homeostasis. The tumor suppressor function of SMAD4 comes from its
ability to inhibit neoplastic transformation at early stages (low-grade PanIN), and inactivating
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mutations of SMAD4 in late stage, high-grade PanIN promote PDAC progression (85). In
addition to the four major driver gene mutations, other mutations including TGFBR1, TGFBR2,
MKK4, RB1, and CCND1 have been identified in recent studies (80).
The identification of driver mutations in PDAC reveal a common genomic landscape
behind PDAC tumorigenesis. However, these recurrent gene mutations are not sufficient to
explain the high variability of survival in PDAC patients (86). In the last decade, many studies
have tried to improve PDAC characterization through different -omics analyses. For example,
PDAC transcriptomic profiling from microarray data identified two PDAC subtypes, classical and
basal-like, based on tumor-specific gene expression. The classical subtype is associated with
better prognosis, whereas the basal-like subtype showed significantly worse survival than the
classical subtype. Transcriptomic-based subtyping, therefore, may represent a better way to
determine the molecular characteristics of PDAC. Further, it may better reflect the patient
outcome and serve as a reference for precision medicine (86).
Cells of origin of PDAC
The cells of origin of PDAC are still debated. According to the cancer stem cell model, a small
fraction of PDAC cells with stem cell properties and high expression of stemness markers such
as CD44, CD24, or DCLK1, have been identified. These cells possess the ability to initiate
tumorigenesis and higher chemoresistance in genetic and xenograft models (74, 80, 87). On the
other hand, PDAC was originally thought to arise from ductal cells due to the morphological
resemblance. Studies using genetically engineered mouse models (GEMMs) showed that KRAS
activation under the ductal cell-specific promoter Hnf1b could give rise to IPMNs (88). Other
studies, however, have demonstrated that mouse models with KRAS activation under the ductal
cell-specific promoter Sox9 failed to yield PanINs and PDAC. Instead, they showed that KRAS
activation in the context of the acinar cell-specific promoter PTF1a drove the process of ADM
and PanINs formation, implying that acinar cells, or at least a subpopulation of cells with acinar
features, can undergo ADM and progress to PanINs (89). Brittany M. Flowers et al. recently
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reported that pancreatic cancer can be derived from both acinar and ductal cells. Further
characterization showed that PDAC of acinar origin exhibits features of the classical subtype,
while PDAC of ductal origin displays features of basal-like subtype (90). Additional studies of the
PDAC cell of origin are required to gain a better understanding of how PDAC arises and its
implications in PDAC initiation.

1.6 What is still missing behind pancreatitis?
Frequently developed in the context of chronic pancreatitis, PDAC is associated with an
inflammatory microenvironment (91). As supported by a substantial body of evidence across a
multitude of experimental models, induction of inflammation in pancreatic tissue expressing
oncogenic KRAS hastens tumor progression (92, 93), inducing the appearance of neoplastic
precursor lesions, such as acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial
neoplasia (PanIN) and eventually evolve into invasive tumors. However, the reasons why
inflammation, an evolutionarily conserved response to damage aimed at reestablishing tissue
integrity upon injury, might be integral to tumorigenesis remain unknown, although recent
evidence suggests that inflammation-induced chromatin changes may play an important role
(69).
Here, to better understand the relationship between inflammatory processes and
pancreatic tumorigenesis, we investigated the long-term consequences of transient
inflammatory events in response to acute pancreatic damage and how resolved inflammation
cooperates with activated oncogenes to drive transformation of normal epithelial cells.
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Chapter 2. Materials and Methods
2.1 Animal models
Mice were housed in a pathogen-free facility at the University of Texas MD Anderson Cancer
Center (MDACC). All manipulations were performed under Institutional Animal Care and Use
Committee (IACUC)-approved protocols.
iKRAS (TetO-LSL-KrasG12D; ROSA26-LSLrtTa-IRES-GFP; p48_Cre) mice were generated as
previously described (94).
Dclk1-DTR-ZsGreen was generated in Dr. Timothy Craig Wang’s lab as described here. The
DTR-2A-Zsgreen-pA-FrtNeoFrt cassette was ligated into a pL451 plasmid. A BAC clone RP23283D6 containing an approximately 50-kb 5′ sequence of the Dclk1 gene–coding region (CHORI)
was isolated and transferred into SW105-competent cells. The correct sequence was confirmed
by using restriction enzyme digestion and PCR in the region of interest. The purified DTR-2AZsgreen-pA-FrtNeoFrt with a probe containing a 75-bp sequence homologous to the BAC
sequence directly upstream and downstream of the ATG in exon 2 of mouse Dclk1 gene was
electroporated into SW105 Dclk1-BAC–containing cells. BAC DNA was isolated, linearized, and
then microinjected into the pronucleus of fertilized CBA × C57BL/6J oocytes at the Columbia
University Transgenic Animal Core facility. One positive founder was identified and backcrossed
to C57BL/6J mice.
B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (referred to as R26_mT/mG) mice were
generated in Dr. Liqun Luo’s lab (95) and purchased from The Jackson Laboratory. These
animals have been bred with B6.129-Bhlha15tm3(cre/ERT2)Skz/J and B6 p48-Cre for tracing
experiments.
B6.129S2-Il6tm1Kopf/J (referred to as Il6-null) mice were generated by Manfred Kopf and
Georges Kohler (Max Planck Institut Fur Immunbiologie, Freiburg Germany) (96) and
purchased from The Jackson Laboratory.
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B6N;129-Egr1tm1Jmi/J (referred to as Egr1-null) mice were generated by Jeffrey Milbrandt,
(Washington University School of Medicine, St. Louis) (97) and purchased from The Jackson
Laboratory.
B6.129-Bhlha15tm3(cre/ERT2)Skz/J (referred to as Mist1_Cre ERT2) mice were generated
by Stephen Konieczny (Purdue University) (98) and purchased from The Jackson Laboratory.
p48-Cre (Ptf1a-Cre) mice have been generated as described in Kawaguchi et al., 2002 (99)
and backcrossed to C57BL/6.
All wild-type animals used as control have been purchased from The Jackson Laboratory.

2.2 Human Samples
Human tissue slides containing cases of acute and chronic pancreatic inflammation were
purchased from US Biomax, Inc. and used for immunofluorescence staining following the
protocol described below.

2.3 In vivo experiments
Induction of acute pancreatitis. Animals of 4-6 weeks were fasted for 12 hours before
receiving 16 injections of caerulein (50 μg/kg) (Sigma-Aldrich) over two consecutive days
(100). Control mice received injections of pyrogen-free PBS. Mice were examined daily for
health conditions and sacrificed at the indicated time points by CO2 asphyxiation and cervical
dislocation.
Survival studies. KRAS expression, in mice recovered from inflammation or in mice that
underwent orthotopic transplantation, was induced and maintained through doxycycline
administration (one injection of 4ug/g IP, followed by feeding mice with doxycycline (2g/l) in
drinking water supplemented with sucrose (20g/l). Mice were then monitored over time for
tumor development by magnetic resonance imaging (see below).
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Orthotopic transplantation. 6–9-week old female mice, upon anesthesia with isoflurane,
were transplanted orthotopically with 2.5 × 10 5 epithelial cells derived from iKRAS spheroids
re-suspended in modified PDEC medium and Matrigel (Corning) (1:1 ratio) (see below
Spheroid Culture). KRAS expression was induced soon after transplantation and mice were
then monitored for tumor development by magnetic resonance imaging.
Subcutaneous transplantation. Tumor masses deriving from orthotopically transplanted
mice were harvested and processed. Briefly, upon mechanical disruption, tumors were
washed twice with G solution (HBSS (Gibco), 5 mg/ml D-Glucose (Sigma Aldrich), 100 μg/ml
Penicillin/Streptomycin (Gibco)) and incubated at 37 °C for 45 min (Collagenase IV (Gibco) Dispase II (Roche), 2 mg/ml) for enzymatic digestion. Cells were then centrifuged and further
digested with 0.25% Trypsin (Gibco) for 5 min at 37 °C to obtain a single cell suspension.
After counting, 5 x 10 5 live cells suspended in PDEC medium + Matrigel (1:1 ratio) were
injected in the flank of recipient animals then monitored for tumor development.

2.4 Histopathology, immunohistochemistry and immunofluorescence
Tissue specimens were fixed overnight in 4% buffered PFA, transferred to 70% ethanol and
then embedded in paraffin using Leica ASP300S processor. For histopathological analysis,
pancreata were sectioned (Leica RM2235) and serial slides were collected. For every series
one section was stained with hematoxylin and eosin and remaining sections were kept for
either immunofluorescence or immunohistochemical analysis. Histological samples were
processed as previously described (101). In brief, after cutting, baking and deparaffinization,
sections underwent antigen retrieval using Citra-Plus Solution (BioGenex) according to
specifications. For immunohistochemistry staining, endogenous peroxidases were
inactivated by 3% hydrogen peroxide and non-specific signals were blocked using 3% BSA,
10% goat serum and 0.1% Triton. Primary antibodies were applied and incubated overnight
at 4°C. ImmPress HRP IgGs (Vector Lab) were used as secondary antibodies and ImmPact
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Nova RED (Vector Lab) was used for detection. Images were captured with a Nikon DS -Fi1
digital camera using a wide-field Nikon Eclipse-Ci microscope.
For immunofluorescence staining, secondary antibodies conjugated with Alexa-488 and
Alexa-555 (Molecular Probes) were used. Fluorescein labeled Dolichos Biflorus Agglutinin
(DBA) (Vector Labs) was used to detect ductal cells when indicated. DAPI nuclear
counterstaining was also performed. Images were captured with a Hamamatsu C11440 digital
camera, using a wide-field Nikon Eclipse-Ni microscope. For spheroid characterization
images were acquired using a Nikon high-speed multiphoton confocal microscope A1 R MP.

Table 1. Primary antibodies for immunohistochemistry and immunofluorescence
Protein name

Brand

Catalog number

α-Amylase

Santa Cruz

sc-46657

CK19

ProteinTech

14965-1-AP

GFP

Cell Signaling

2956

NF-kB p65 (Ser536)

Abcam

ab86299

NF-kB p65 (Ser281)

Affinity

AF3393

Cleaved Caspase 3

Cell Signaling

9661

EGR1

Cell Signaling

4153

CD45

eBioscience

14-0451-82

Ki67

Abcam

ab15580

IL-6

Abcam

ab6672

pSTAT3 (Tyr705)

Cell Signaling

9145

DCLK1

Abcam

ab31704

E-Cadherin

Thermo Fisher Scientific

131900

H3K9me3

Abcam

ab8898

For GFP detection in pancreatic tissue reconstituted through spheroid injection, samples were
fixed overnight in 4% buffered PFA at 4°C, transferred to PBS + Sucrose 20 % and embedded
in OCT Compound (Tissue-Tek). Specimens were cryosectioned (Leica CM1950) and dried
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at room temperature for 10 minutes before DAPI nuclear counterstaining and image
acquisition.

2.5 Image quantification.
For CD45/Ki67 IHC quantification, 10X-magnification fields of whole-mount pancreas per
mouse were captured and the average number of CD45 or Ki67-positive cells were counts
with ImageJ. Data from each experimental group were then normalized to untreated control.
Images used for quantification were captured with a Nikon DS-Fi1 digital camera using a
wide-field Nikon Eclipse-Ci microscope.
For quantification of KRAS-driven changes in pancreatic tissues over time, we
implemented a computational approach for hematoxylin-eosin (H&E) color deconvolution
(102). Specifically, whole pancreas images of H&E staining were acquired, normalized, and
subjected to color deconvolution using a Gaussian filter with 3 pixels in radius. Staining
intensity of eosin and hematoxylin for each pixel was then quantified and plotted in a 2D space.
Based on tissue differential affinity for histological dyes, this approach enables the
assignment of pixels to distinguish tissue structures (normal or tumoral), allowing the
reconstruction and quantification of tissue histological composition with high precision.
The following quantification were done via MATLAB. Automatic image segmentation and
quantification was done using MATLAB (The MathWorks, Inc.). Otsu's thresholding method
and marker-controlled watershed algorithm was employed to segment and specify nuclear
regions of individual cell. Expression levels of each markers in the individual segmented area
was then quantified by pixel intensity.
For Cleaved Caspase-3 (CC3) immunostaining quantification, we calculated the area size
of caspase3-positive regions and DAPI-positive regions in each image under 20x
magnification respectively. To normalize the cleaved-caspase 3 staining, we divided each
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value of caspase3-positive area size by DAPI-positive area size and showed data in dot plot.
Each dot represented CC3/DAPI ratio per field.
For quantification of inflammation-induced EGR1 expression in wild-type mice, nuclei
from 40X magnification fields of pancreatic tissues in each experimental group were counted
and used for the analysis. Violin plots in log scale were used for data representation.
For quantification of inflammation-induced EGR1 expression in IL6-null mice, nuclei
from 20X magnification fields of pancreatic tissues in each group were counted and used for
the analysis. Violin plots in log scale were used for data representation.
For quantification of pNF-kB and pSTAT3 in epithelial cells, we first calculated the level
of E-cadherin intensity to set a threshold that segregated E-cadherin-positive and E-cadherinnegative cells. The expression level of pNF-kB and pSTAT3 was then quantified by pixel
intensity in E-cadherin-positive cells. Nuclei from 20X magnification fields in each group were
used for quantification. The quantified data were plotted in a violin graph with the intensity
level in log scale.
For quantification of CK19/amylase ratio for ADM, the total pixel intensity of CK19 and
amylase from 20X magnification fields in each group had been quantified. Each dot
represented the ratio of CK19/amylase signal calculated in each field.
For quantification of spheroids size, 4X-magnification fields representing spheroids culture
from multiple biological replicates each experimental group were analyzed with ImageJ
(https://imagej.nih.gov/ij/) expressing spheroids area as pixels. Images used for quantification
were captured with a Cool-SNAP ES 2 digital camera using a wide-field Nikon Eclipse-Ti
microscope.

2.6 Magnetic resonance imaging. A 7T Bruker Biospec (BrukerBioSpin), equipped with
35mm inner diameter volume coil and 12 cm inner-diameter gradients, was used for MRI
imaging. A fast acquisition with relaxation enhancement (RARE) sequence with 2,000/39 ms
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TR/TE, 256x192 matrix size, r156uM resolution, 0.75 mm slice thickness, 0.25 mm slice gap,
40 x 30 cm FOV, 101 kHz bandwidth, and 4 NEX was used for acquired in coronal and axial
geometries a multi-slice T2-weighted images. To reduce respiratory motion, the axial scan
sequences were respiratory gated. All animal imaging, preparation, and maintenance was
carried out in accordance with MD Anderson’s Institutional Animal Care and Use Committee
policies and procedures.

2.7 In vitro experiments
Spheroid culture. Spheroids cultures were maintained as previously described (103-105)
with some major modifications. Briefly, pancreata from age matched control animals and
animals that underwent a 4-week recovery from acute pancreatitis were harvested and kept
on ice before processing. Upon mechanical disruption, of note we did not perform any ductal
enrichment, tissues were washed twice with G solution (HBSS (Gibco), 5 mg/ml D-Glucose
(Sigma Aldrich), 100 μg/ml Penicillin/Streptomycin (Gibco)) and incubated at 37 °C for 45 min
(Collagenase IV (Gibco)-Dispase II (Roche), 2 mg/ml) for enzymatic digestion. Cells were
then centrifuged and further digested with 0.25% Trypsin (Gibco) for 5 min at 37 °C to obtain
a single cell suspension. Cells were then wash twice with PBS and plated on Collagen IV coated plates (Corning) in modified PDEC medium: DMEM/F12 1:1 supplemented with 2.5
mM L-Glutamine, 15mM HEPES Buffer (HyClone), 5 mg/ml D-Glucose (Sigma Aldrich), 1.22
mg/ml Nicotinamide (Sigma Aldrich), 5 nM 3,3,5-Tri-iodo-L-thyronine (Sigma Aldrich), 0.5 μM
Hydrocortisone Solution (Sigma Aldrich), 100 ng/ml Cholera Toxin (Sigma Aldrich), 0.5 %
Insulin-Transferrin-Selenium + (BD), 100 μg/ml Penicillin/Streptomycin (Gibco), 0.1 mg/ml
Soybean Trypsin Inhibitor (Sigma Aldrich), 20 ng/ml EGF (Peprotech), 25 μg/ml Bovine
Pituitary Extract (Invitrogen), and 5% Nu Serum IV Culture Supplement (BD). After 2 days the
supernatant cellular fraction was harvested and replated in PDEC-Matrigel (Corning) (1:1.5
ratio). Spheroids were then passaged every 7-10 days at low confluency.
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CD45 cell isolation, spheroid co-culture and Hyper-IL6 treatment. At 24 hours after the
last injection of caerulein pancreata were harvested and cells isolated following the protocol
described above besides that no trypsin digestion was performed in order to preserve surface
antigens. After digestion pancreata were then filtered through a 45 µm nylon mesh to separate
epithelial structures from other cells. After filtration CD45-positive cell fraction was purified
with EasySep™ Mouse Biotin Positive Selection Kit (StemCell Technologies) following the
manufacturer’s protocol using an anti-CD45-Bio antibody (30-F11, eBioscience). Purity (~9598%) of isolated cells was checked by flow cytometry using SA-APC. Isolated CD45-positive
cells were then suspended in modified PDEC medium and used for setting cocultures with
epithelial spheroids. Briefly, iKRAS epithelial cells from spheroids never exposed to
inflammation were plated in PDEC-Matrigel mix into high-density pore transwell (Corning, Inc.)
then inserted in a 6-well plate containing the purified CD45-positive cells suspended in
modified PDEC media (2 ml/well). After one week of co-culture, spheroid were collected and
reseeded in ‘conventional’ modified PDEC-Matrigel. For Hyper-IL6 experiments spheroid
were plated in PDEC-Matrigel in presence of 200 ng/ml of Hyper-IL6 for 24 hours. Hyper-IL6
was kindly provided by Dr. Stefan Rose-John.
Reverse Transcription and Quantitative Real-Time PCR. Mouse pancreata were snapfrozen and grinded into powder with liquid nitrogen followed by total RNA extraction using
TRIzol (Thermo Fisher Scientific) according to manufacturer’s instructions. 1 µg RNA was
used to generate cDNA using Thermo Fisher Scientific SuperScript™ VILO™ Master Mix. 10
ng of cDNA was used for quantitative PCR using Applied Biosystems PowerUp SYBR Green
PCR Master Mix with gene-specific primers. Gene relative expression level was determined
by the comparative CT (ΔΔCT) method and normalized to GAPDH.
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Table 2. Primer sets used for iKRAS expression detection
Primer name

Primer sequence

miKrasG12D-F

CAAGACAGGGTGTTGACGATG

miKrasG12D-R

GCTGCAGGAATTCGATATCTGC

mKras-wt-F

AGAGAGGCCTGCTGAAAATG

mKras-wt-R

CCCTCCCCAGTTCTCATGTA

m28S-F

TCATCAGACCCCAGAAAAGG

m28S-R

GATTCGGCAGGTGAGTTGTT

mGAPDH-F

ACCTGCCAAGTATGATGAC

mGAPDH-R

CCACCCTGTTGCTGTAG

2.8 Flow cytometry analysis and single-cell sorting
For flow cytometry analysis sample acquisition was carried out using a BD FACS Canto II or
LS-Fortessa cytometers (BD Biosciences), cell sorting was carried out using BD FACS Influx
cell sorter (BD Bioscience). All flow cytometry experiments were performed at the MD
Anderson South Campus Flow Cytometry and Cell Sorting Facility. Data were analyzed by
BD FACSDiva or FlowJo (Tree Star) excluding doublets and dead cells (DAPI positive) at the
time of the gating-strategy.
For purity assessment of isolated inflammatory cells, samples labeled with anti CD45Bio (eBioscience) antibody and prepared for CD45 isolation (before and after EasySep
purification) were stained with SA-APC (eBioscience) before acquisition.
For BrdU incorporation assay, epithelial spheroids derived from mice pre-exposed or not to
caerulein were pulsed with BrdU for 16 hours, collected and stained according to BrdU Flow Kit
specifications (BD Biosciences) followed by flow cytometry analysis. DAPI was used for
determination of DNA content.
For DCLK1-positive cell sorting, pancreatic single cell suspensions were obtained from
pancreata of Dclk1-DTR-zsGreen mice and wild-type control animals following the
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mechanical disruption and enzymatic digestion described above. 1μg/ml DAPI (Thermo
Fisher) was added to samples to exclude dead cells. Cells isolated from wild-type animals
was used to set the sorting gates. Both zsGreen-positive and negative fractions of cells from
Dclk1-DTR-zsGreen digested pancreata were collected and assessed for establishing
spheroid cultures.

2.9 Cytokine detection
Media conditioned by CD45-positive cells isolated from Caerulein-treated pancreata were
collected at indicated time points and analyzed by Mouse Inflammatory Cytokines Multi Analyte ELISArray Kit (Qiagen). Measurements were repeated multiple times from
independent wells according to the manufacturer protocols. Absorbance was read by
PHERAStar HTS microplate reader (BMG Labtech).

2.10 Serum Amylase and LDH detection
Blood was drawn from retro orbital vein at 24 hours from the first injection of Caerulein (after
8 injections) and collected in BD Microtainer® blood collection tubes (BD Bioscience). After
30 minutes at room temperature samples were centrifuged for 10 min to separate the clot
from the serum, samples then were aliquoted and stored at -80 °C. The concentration of
pancreatic amylases and lactate dehydrogenase in the serum was measured using
respectively the Amylase Assay Kit (Abcam) and Mouse LDH/Lactate Dehydrogenase ELISA
Kit (LifeSpan Biosciences) according to specification.

2.11 Immunoblotting
After washing in ice-cold PBS, collected cells were pelleted and resuspended in RIPA buffer
with proteinase and phosphatase inhibitors. Lysates were then centrifuged at 14,000 rpm for
20 min at 4 °C to eliminate debrides. Protein concentrations were assessed using the DC
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Protein Assay Kit (Biorad). Samples were loaded on a 5-15% gradient Mini-Protean TGX
Precast Gels for the SDS-PAGE and then transferred onto PVDF membranes according to
standard protocols. Membranes were incubated with indicated primary antibodies, washed,
and probed with HRP-conjugated secondary antibodies. Protein specific signals were
identified by chemiluminescence upon film exposure.

Table 3. Primary antibodies for immunoblotting
Protein name

Brand

Catalog number

EGR1

Cell Signaling

4153

pSTAT3 (Tyr705)

Cell Signaling

9145

STAT3

Cell Signaling

4904

P16-INK4A

Abcam

ab81278

Vinculin

Sigma-Aldrich

05-386

2.12 CyTOF immunophenotyping
Metal-labeled antibodies against cell surface markers were purchased from DVS Sciences. A
single cell suspension was obtained as described above (CD45-positive cells isolation section)
from pancreatic tissue undergone Caerulein-induced inflammation and harvested after 24
hours from the last Caerulein injection. The cells were depleted of erythrocytes by hypotonic
lysis. After washing the samples were centrifuged and resuspended in a PBS + 0.5% BSA
solution with a mix of all surface antibodies and incubated at 4 °C for 1 hour. Cells were then
washed once and incubate with 25 uM Cisplatin for 1 min for the viability staining. The fixation
and permeabilization step was carried out using Fixation/Permeabilization Solution kit (BD
Biosciences) for 20 minutes. After washing the step of intracellular staining was performed
incubating the cells in a PBS + 0.5% BSA solution with the IL6_167Er antibody (FluidiGM) for
1 hour. After washing samples were incubated with MAXPAR®Nucleic Acid Intercalator-Ir
(DVS Sciences) at 4 oC overnight to stain the nuclei and analyzed with CyTOF instrument
(DVS Sciences) in the Flow Cytometry and Cellular Imaging Core Facility at M.D. Anderson
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Cancer Center. Data were processed with FlowJo (Tree Star) and viSNE. The following
markers were used to define different immune populations: CD45_89Y, CD68 145Nd, CD11b
148Nd, F4/80_173Yb, CD4_115In, CD8a_168Er, B220_176Yb, NK1.1_170Er.

2.13 RNA-Seq Data Analysis
Total RNA was extracted from C57BL6 WT spheroids using RNeasy Mini Kit (Qiagen)
following manufacturer instructions. Quantity and quality were measured using the RNA Nano
kit on the Agilent Bioanalyzer (Agilent Technologies). Paired-end multiplex sequencing of
samples was performed on the Illumina HiSeq 2000 sequencing platform.
After quality filtering according to the Illumina pipeline, 76 bp paired‐end reads were aligned to
the mm10 mouse reference genome and to the Mus musculus transcriptome (GRCm38) using
STAR (version 2.6.0c) (106) and only properly paired mapped reads were retained. At the gene
level, expression counts were estimated using featureCounts (Rsubread version 1.5.1) (107),
summarized across all exons as annotated in the GENCODE v.19, with option “--largestOverlap”.
Both coding and long noncoding genes with a minimum of 0.5 Count per Million read in at least
three samples were retained for downstream analyses. Differential expression analysis in three
biological replicates of control (Ctrl) and in four treatment replicates (Post-CAE) were identified
using EdgeR R-package (version 3.2.2)(108) with trimmed mean of M normalization and a
generalized linear model (GLM) likelihood ratio test (109). To minimize the effect of batch effect,
‘batch factor’ was included as a covariate in the GLM likelihood ratio test design matrix. Then,
the fragments per kilobase per million reads method (FPKM) values were used as expression
unit. Genes were identified as differentially expressed (DEGs) when the following criteria were
met: log2 of the fold-change (FC) ≥ 0.8; false discovery rate (FDR) < 0.05; at least 1 FPKM
in all samples in one or both conditions.

For the Gene Set Enrichment Analysis (GSEA)(110) all genes were ranked by log2(FC)
and 1000 gene set permutations were performed to assess the statistical significance.
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Gene sets background was built using the hallmark gene signature, downloaded from
The Molecular Signatures Database (MSigDB). An additional gene set named
‘Development/Progression’ was constructed from Reichert et al.(111) considering 452
genes coregulated in epithelial pancreatic mouse cells during acute pancreatitis and
KRAS-G12D dependent carcinogenesis (tumor progression).
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com; Redwood
City, CA) was carried out using a commercial software.

2.14 H3K27Ac ChIP‐seq Data Analysis
ChIP‐seq was carried out using previously described protocols (112) on an Illumina HiSeq 2000
platform. Short reads obtained were quality filtered according to the Illumina pipeline and then
mapped to the mouse mm10 reference genome using Bowtie2 v2.2.6(113) with the “--verysensitive” preset of parameters. Reads that did not align to the nuclear genome or aligned to the
mitochondrial genome were removed. Moreover, duplicate reads were marked and removed
using SAMtools(114). Peak calling vs. the input genomic DNA was performed using MACS
1.4(115) using the “--nomodel” and “--shiftsize 125” flags and arguments. A matched input was
used as control. Peaks with a P‐value > 1E‐10, both ChIP vs. input DNA and ChIP vs. ChIP, and
those blacklisted by the ENCODE consortium analysis of artifactual signals in mouse genome
(https://sites.google.com/site/anshulkundaje/projects/blacklists)

were

removed

using

bedtools(116). All ChIP-seq peaks that were no more than 3 kb away from annotated gene TSS
(GENCODE v19) were selected as promoter regions, using annotatePeaks script from HOMER
package(117). Regions other than promoter regions were considered distal regions

2.15 Single-cell RNA Sequencing
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Pancreata were harvested from C57BL/6J wild-type mice at different time points before and after
acute inflammation and digested as described above to obtain single cell suspension. After
CD45-positive cells depletion, primary cells derived from 3 pancreata were mixed for each time
point, and 10,000 cells were captured followed by library preparation using 10X Chromium single
cell 3’ V3 chemistry according to manufacturer’s protocol. Libraries were then multiplexed and
sequenced on a single lane of NovaSeq6000 S2‐100 flow cell (Illumina).
scRNA-seq data processing and analysis. Raw sequencing data processing, QC, data
filtering and normalization. The raw sequencing data were pre-processed (demultiplexed cellular
barcodes, read alignment, and generation of gene count matrix) using Cell Ranger Single Cell
Software Suite provided by 10x Genomics. Detailed QC metrics were generated and evaluated.
Genes detected in <0.1% of total sequenced cells and cells where < 200 genes had nonzero
counts were filtered out and not included in the analysis. Low quality cells, where >15% of the
counts were derived from the mitochondrial genome, were also discarded. Cells with detected
genes > 8,000 were discarded to remove likely doublet or multiplet captures. Of 40,028
sequenced cells, 33,681 (84%) passed quality filtering with an average of ~110,261 reads
aligned per cell. Possible batch effects were then evaluated and corrected using FastMNN (118)
with default parameters (d = 50, k =20). Seurat was applied to the filtered matrix to obtain the
normalized count as previously described (119).
Dimensionality reduction, unsupervised cell clustering, determination of major cell types
and cell states. Seurat (120) was applied to identify highly variable genes for unsupervised
clustering. The first 20 Principal Components and the top 2000 highly variable genes were used
for clustering at a resolution of 0.5. The Uniform Manifold Approximation and Projection (UMAP)
method was used for dimensionality reduction and 2-D visualization of the single cell clusters.
Feature plots were generated of suggested cell-lineage specific markers, and differentially
expressed genes (DEGs) were identified using Seurat followed by a manual review process to
determine major cell types and cell states according to the enrichment of specific markers in
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each cell cluster, as previously described (121). The gene set variation analysis (GSVA) software
package (122) was applied to assess the enrichment of the gene set ‘Development/Progression’
described above in different time points. Ingenuity Pathway Analysis (IPA, Ingenuity® Systems;
Redwood City, CA) was carried out using a commercial software.

2.16 ATAC-seq
ATAC-seq was performed as previously described (123) with minor modifications. For
pancreatic cells ATAC-seq, pancreata were harvested from C57BL/6J wild-type mice at
different time points before and after acute inflammation and digested as described above to
obtain single cell suspension. Primary cells derived from 3 pancreata were mixed for each time
point followed by epithelial cells purification. In brief, cells were stained with anti-EpCAM
biotinylated antibody (G8.8, eBioscience) and the enrichment of epithelial cells was performed
with EasySep™ Mouse Biotin Positive Selection Kit (StemCell Technologies) according to the
manufacturer’s protocol. 50,000-100,000 epithelial cells were lysed with ATAC lysis buffer for
5 minutes on ice followed by Tn5 tagmentation for 30 minutes at 37 °C. After indexing and PCR
amplification, DNA libraries were multiplexed and sequenced on a single lane of Hiseq4000 with
76 PE configuration. For pancreatic DCLK1-positve cell ATAC-seq, pancreata were
harvested from Dclk1-DTR-zsGreen mice at different time points before and after acute
inflammation and digested as described above to obtain single cell suspension. 50,000-100,000
DCLK1-positive epithelial cells (ZsGreen-positive cells) from each sample were lysed with ATAC
lysis buffer for 5 minutes on ice followed by Tn5 tagmentation for 30 minutes at 37 °C. After
indexing and PCR amplification, DNA libraries were multiplexed and sequenced on a single lane
of HiseqX with 150 PE configuration.
ATAC‐seq Data Analysis. Paired-end ATAC-seq fragments of mouse samples were aligned to
mouse reference build GRCm38/mm10 using Bowtie2 v2.2.6(113). Reads that did not align to
the nuclear genome or aligned to the mitochondrial genome were removed and duplicate reads
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were marked and removed using SAMtools(114). Read positions were corrected for transposon
insertion offset as described (124), then, only uniquely mapped paired-end reads were kept for
further analysis. Differentially open chromatin regions were obtained in pairwise comparisons
between day 28 vs untreated samples using MACS2 (version 2.1.0.20150731)(115) with
parameters: --nomodel --nolambda --extsize 146 -q 1E‐4. All ATAC-seq peaks that were no more
than 3 kb away from annotated gene TSS (GENCODE v19) were selected as promoter (proximal)
regions, using annotatePeaks script from HOMER package (117). Regions other than promoter
regions were considered distal regions. GREAT functional enrichment analysis (version 3.0.0)
(125) was used to catalog the differential peaks with default parameter.

2.17 Motif enrichment analysis.
Statistically over-represented motifs for known TFs were identified using the Analysis of Motif
Enrichment (AME) tool of the MEME suite (126), with default parameters except for the motif
score P-value setting to 1e-04. A collection of position‐specific weight matrices (PWMs) was
obtained as described in Diafera & Balestrieri et all (127). To identify PWMs enriched in the
promoter regions of deregulated genes from RNA-seq and Single-cell RNA-seq sets, a window
of 600 bp (-500 and +100 bp relative to TSS) was considered and a set including all GENECODE
gene promoters was used as background. For the set of differential acetylated regions from
ChIP-seq, we compared the acetylated enhancers with the set of mouse enhancers in the
FANTOM5 collection (128) using a window of ±250 bp around enhancer centers. For the set of
differential open chromatin regions from ATAC-seq, we used a window of ±73 bp around summit
and compared to undifferential regions as background.

2.18 Statistical analysis
In vitro and in vivo data are presented as the mean ± standard deviation (SD). Statistical
analyses were calculated using a two-tailed unpaired Student’s t-test or one-way ANOVA
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after the evaluation of variance. For survival studies mice were randomized to the
experimental groups and results analyzed with a log-rank (Mantel–Cox) test and expressed
as Kaplan–Meier survival curves.
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Chapter 3. Results
3.1 Transient inflammation promotes tumorigenesis long after its resolution
To investigate the long-term effects of inflammation on the transformation of normal
pancreatic epithelial cells, we used caerulein (hereafter CAE), a decapeptide analog of
cholecystokinin (129), to trigger damage and subsequent inflammation in a well-characterized
PDAC mouse model (inducible KRAS, iKRAS) in which oncogenic KRAS G12D expression is
induced in the pancreas via doxycycline administration (TetO-LSL-KrasG12D_ROSA26-LSLrtTaIRES-GFP_p48-Cre) (94, 101, 130)(Figure 2).

Figure 2. Inducible KRAS mouse model.

To verify inducible KRAS mutant expression in iKRAS mouse model was strictly
regulated, we designed primers specifically recognizing 3’ UTR of iKRAS transgene and
endogenous wild-type KRAS as internal control as previously described (PMID: 22541435),
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and performed QPCR to detect KRAS mutant expression level in pancreatic cells with or
without doxycycline induction. To ensure primer specificity, we also included wild-type mice
as negative control. As expected, we detected KRAS expression only after doxycycline
treatment and no significant differences of KRAS mutant level between wild -type control and
untreated mice were observed, indicating that without doxycycline induction, there is no KRAS
mutant leakage (Figure 3, left panel). Wild-type KRAS and 28S were served as internal
control, which expression levels were not modified by doxycycline treatment (Figure 3,
middle and right panel).

Figure 3. iKRAS model is tightly regulated by doxycycline administration. Pancreatic RNA
from wild-type control and iKRAS mice with or without doxycycline treatment are extracted
followed by QPCR with KRAS mutant-specific, wild-type KRAS specific, 28S and GAPDH
primers. Relative expression level of each gene is normalized to GAPDH and wild-type control.
Data shown as representative of two biological replicates.

To avoid confounding effects linked to chronic CAE administration, such as stromal and
microenvironmental remodeling, we used a 2-day CAE administration protocol to induce acute
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inflammation (100), whereas control animals received intra-peritoneal injections with PBS on the
same schedule (Figure 4).

Figure 4. Schematics representing the experimental design of acute inflammation and
KRAS induction in iKRAS mice. Briefly iKRAS mice are treated for two days (-D1, D0) with
caerulein (CAE) to induce acute pancreatitis and followed for 4 weeks. When pancreata are fully
recovered from pancreatitis (D28), CAE-treated and control mice are put on doxycycline to
induce the expression of mutated Kras and observed for tumor development.

Immediately after CAE administration, we observed transient pancreatic inflammation,
with edema and inter/intra-lobular infiltration of inflammatory cells, followed by rapid restoration
of tissue integrity by day 7 (Figure 5).
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Figure 5. Histological analysis of pancreatic samples at different time points after
pancreatitis induction. Edema and infiltration appear at the end of caerulein (CAE) treatment,
increase at day 1 (D1) and are completely resolved by day 7 (D7) when pancreata reacquire the
normal structure. Scale bar=100 µm.

Immunostaining was consistent with the histological analysis, revealing that inflammatory
cell infiltration (CD45-positive cells) and proliferation (Ki67 staining) present at day 1 (D1) postCAE treatment returned to pre-CAE levels by day 28 (Figure 6), indicative of a complete
histological resolution.
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Figure 6. Immunostaining for CD45 and Ki67 of pancreatic samples at different time points
after pancreatitis induction. Strong inter- and intra-lobular infiltration of CD45-positive cells is
present at the end of CAE and day 1 (D1) after CAE treatment and signal disappears by day 7
(D7). Similarly, Ki67 staining is strongly increased at day 1 (D1) when many different cells show
positivity, then signal decreases over time and disappears by day 28 (D28). Scale bar= 100 µm.
Quantification of CD45 or Ki67-positive cell number relative to untreated control is shown in right
panel. n=3 per group. Data are shown as mean ± SD. Statistical significance is assessed with
one-way ANOVA.
In addition, we observed strong nuclear staining of two pivotal transcriptional activators of
inflammation, NF-kB (131) and STAT3 (132), in epithelial and stromal cells immediately following
the induction of pancreatitis (Figure 7).

a

b
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Figure 7. The expression of inflammation markers pNF-kB and pSTAT3 in pancreatic
samples at different time points after pancreatitis induction. a) Immunofluorescence for NFkB (p-Ser536, Red), E-cadherin (Green) and DAPI (Blue) of pancreatic samples at different time
points before and after CAE treatment. Scale bar=200 µm or scale bar= 50 µm for main or inset
images, respectively. n=3 mice per group. Quantification of pNF-kB expression level in Ecadherin-positive cells are shown as violin lot with log scale. Statistical significance is assessed
with one-way ANOVA. b) Immunofluorescence for pSTAT3 (p-Tyr705, Red), E-cadherin (Green)
and DAPI (Blue) of pancreatic samples at different time points before and after CAE treatment.
Scale bar=200 µm or scale bar= 50 µm for main or inset images, respectively. n=3 mice per
group. Quantification of pSTAT3 expression level in E-cadherin-positive cells are shown as violin
lot with log scale. Statistical significance is assessed with one-way ANOVA.

The normalization of these two transcription factors, together with recovery of the normal
pancreatic histology, suggested that the inflammatory response was extinguished one-week
post-CAE treatment. Therefore, we explored the effects of oncogenic KRAS after resolution of
this single inflammatory event by inducing its expression at 28 days after the initial CAE protocol
and monitoring tumor development (Figure 4). CAE-treated mice developed tumors with high
penetrance and succumbed to disease earlier than control animals (median survival of 190 days
in CAE-treated versus undefined in control animals; p=0.01) (Figure 8 and Figure 9).
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Figure 8. Kaplan-Meier survival of mice previously exposed to inflammation (caerulein,
n=21) or control mice (untreated, n=10) after KRAS induction.

Figure 9. Histological and molecular analysis of pancreatic tissues with or without CAE
treatment after KRAS induction. H&E staining and immunofluorescence for cytokeratin-19
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(CK19, Green) and amylase (Red) of pancreata of matched caerulein treated/untreated animals
after Kras induction. Cell nuclei are stained with DAPI (Blue). Scale bar=200 µm.

CAE-treated mice developed tumors with high penetrance was also confirmed by nuclear
magnetic resonance (Figure 10).

Figure 10. MRI images of matched CAE- and PBS-treated iKRAS animals. Pancreatic
structures (orange highlighted) are shown in two different planes. In CAE-treated animal, the
pancreas appears enlarged and the structure appears not homogeneous due to an ongoing
pancreatic tumor.

To explore what happens to the pancreatic tissue harboring resolved inflammation over
time after KRAS induction, we induced oncogenic KRAS expression at 1 month after
inflammation in our iKRAS mouse model, and harvested pancreata at 2, 3, and 4 months after
KRAS induction (Figure 11).
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Figure 11. Schematics representing the experimental design for KRAS-driven changes
overtime. In brief, KRAS was induced in iKRAS mice at 1 month after acute pancreatitis and
pancreata sampled for histological analysis at 2, 3 and 4 months after KRAS induction. Mice that
did not receive acute inflammation were used as control.
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Because in mice with resolved inflammation, epithelial alterations induced by KRAS are
multifocal and composed of synchronous lesions frequently characterized by a mixture of distinct
histopathological features (low and high grade) (Figure 12), to better capture and quantify the
true extent of KRAS-driven changes in pancreatic tissues over time, we implemented a
computational approach for hematoxylin & eosin (H&E) color deconvolution (102).

Figure 12. Resolved inflammation cooperates with KRAS activation to generate tumors
with mixture of distinct histopathological features. Panoramic view and higher
magnifications of a pancreas from a mouse previously exposed to inflammation at 3 months after
KRAS induction showing multifocal lesions characterized by different histopathological grades
denoting the complexity of the histological samples.
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Specifically, whole pancreas images with H&E staining were acquired, normalized, and
subjected to color deconvolution using a Gaussian filter with 3 pixels in radius. Staining intensity
of H&E for each pixel was then quantified and plotted in a 2D space (Figure 13a,b). Based on
tissue differential affinity for histological dyes, this approach enabled the assignment of pixels to
distinct tissue structures (normal or tumor), thus enabling a highly precise reconstruction of the
tissue histological composition. For example, pixels corresponding to tumor lesions are
characterized by lower H&E intensity (Red gate), while pixels corresponding to normal pancreata
are populated by well-differentiated cells characterized by large eosinophilic cytoplasm and
hematoxylin-intense heterochromatic nuclei (Yellow gate). Similarly, lymphoid or splenic tissues,
populated by highly packaged cells with a high nuclear/cytoplasm ratio, generate very strong
signals in hematoxylin but relatively dimmer signals in eosin (Black gate) (Figure 13b). Upon
tissue segmentation, reconstructed whole pancreatic images (Red-neoplastic lesions; Yellownormal tissue; Black-lymphoid tissue) were overlaid to the original histological samples to verify
accuracy of the procedure (overlapped tumor lesions appear highlighted as greyish/blueish)
before running quantification analysis (Figure 13c,d).
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Figure 13. Computational approach for tumor lesion quantification. a) Hematoxylin & eosin
(H&E) images of pancreas at 4 months after KRAS induction with (left) or without (right) preexposure to inflammation (caerulein treatment) serve as an example. Scale bar= 2000 µm. b)
Deconvolution of H&E colors and representation of histological images as 2D dot plots based
on hematoxylin and eosin pixel intensity (X and Y axis, respectively). Due to the differential
affinity for histological dyes, normal pancreatic tissue and tumor lesions generate distinct pixel
distributions in the 2D space that enables their precise identification and quantification through
a simple gating strategy: normal pancreas (yellow gate), tumor lesions (red gate), lymphoid
tissues (black gate). c) Reconstructed tissue images based on the applied gating strategy.
Tumors appear as red, normal pancreas as yellow, and lymphoid tissue as black. d) Quantifying
masks for tumor are overlaid to the original images for validating accuracy.
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Histological analysis of neoplastic lesions in pancreata of mice pre-treated with CAE or
PBS (untreated control) at 2, 3 and 4 months after KRAS induction revealed that pancreata
lesions of mice pre-exposed to inflammation had significantly larger/increased number of
neoplastic lesions than those in control mice (Figure 14).
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Figure 14. Histopathological evaluation and quantification of KRAS-driven changes over
time in pancreata previously exposed to an inflammatory event (caerulein treatment) or
PBS. For each time point, 4 images are shown per experimental group. Upper images,
hematoxylin & eosin (H&E) staining at low magnification (left) and corresponding quantification
mask (right); lower images, high magnification detail of H&E (left) and corresponding
quantification mask (right). In high magnification H&E panels, orange circles highlight tumor
lesions. Color code for quantifying mask: Red=tumor lesion, Yellow=normal pancreatic tissue,
Black=spleen or lymphoid tissues. Scale bars correspond to 2000 µm and 100 µm in upper and
lower images, respectively.

Evaluation of tumor burden, as the ratio of neoplastic lesion/normal pancreas
(Red/Yellow), showed minimal evolution in control animals with respect to animals pre-exposed
to inflammation. Specifically, in animals pretreated with CAE, tumor burden increased in a timedependent manner, indicating that oncogenic KRAS in a context of resolved inflammation leads
to accelerated tumorigenesis (Figure 15).
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Figure 15. Quantification of tumor burden (lesions to normal pancreas ratio) over time.
Data are shown as mean ± SD, n=3 mice. Statistical significance is assessed with unpaired
Student’s t-test. ns= non-significant.

Strikingly, the cooperation between oncogenic KRAS and resolved inflammation
extended far beyond 28 days, as we documented accelerated tumorigenesis even when KRAS
was activated 3 months after a single inflammatory event (median survival of 217 days in CAEtreated versus undefined in untreated animals; p=0.0026) (Figure 16).
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Figure 16. The effect of resolved inflammation can last for at least three months in vivo.
a) Schematics representing the experimental design for (b) and (c). In brief, KRAS is induced in
iKRAS mice at 3 months after acute pancreatitis. Mice without acute inflammation are included
as control. Animals are followed for tumor development. b) Kaplan-Meier survival analysis of
mice in which KRAS is activated after 3 months after acute pancreatitis (caerulein, n=22) or in
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control animals (untreated, n=12). c) H&E staining of pancreata from untreated and caeruleintreated matched mice show extensive tumor lesions subverting the pancreatic structures in
animals pre-exposed to inflammation (Caerulein). Only small lesions are detected in untreated
controls. Scale bar= 200 µm.

To exclude the possibility that the phenomenon we observed were caused by CAE itself
but not inflammation, we used an orthogonal approach in which inflammation was induced by
pancreatic ductal ligation and was independent of CAE treatment. We also demonstrated that
the effect of resolved inflammation appears to have similar penetrance as conventional protocols
of accelerated pancreatic tumorigenesis in which inflammation is induced in the context of an
ongoing oncogenic signaling (Figure 17).

Figure 17. Kaplan-Meier survival of mice same as in Figure 8 also showing mice in which KRAS
expression was induced before induction of inflammation (Conventional, n=7) and mice in which
inflammation was triggered by pancreatic ductal ligation followed by KRAS induction as a
caerulein-independent inflammation control (n=5).
Overall, these data demonstrate that transient inflammatory events have persistent
effects on normal epithelial cells and can cooperate with oncogene activation long after their
resolution.
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3.2 Long-term effects of resolved inflammation are cell autonomous
To determine whether differences in outcome between CAE-treated and untreated
animals resulted from epithelial cell-autonomous effects or from the influence of enduringly
activated stroma, we established epithelial cultures from pancreata of mice 4 weeks after acute
CAE treatment or PBS-treatment in control animals. Pancreatic cells were cultured as spheroids,
an effective culturing system that allows the expansion of 3D epithelial structures. Spheroids
derived from CAE-treated wild-type animals, although numerically and morphologically similar
(Figure 18a-c), showed an increased size with respect to spheroids derived from control animals,
suggesting that epithelial cells previously exposed to inflammation can expand more efficiently
in vitro (Figure 18d,e).
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Figure 18. Spheroids derived from mice pre-exposed to CAE exhibit higher proliferative
potential compared to untreated control. a) Quantification of spheroids number per 10 5 cells
plated from pancreas of wild type mice recovered from inflammation (CAE, n=3) or controls
(CTRL, n=3). Data are shown as mean ± SD. Statistical significance is assessed with unpaired
Student’s t-test. ns= non-significant. b) Immunofluorescence for cadherin E (CDH1-Red),
Cytokeratin 19 (CK19-Green) and DAPI (Blue) of spheroids derived from control or CAE
recovered animals. Scale bar=20 µm. c) 3D reconstruction of representative spheroids in
confocal microscopy stained with DBA (Green) and DAPI (Blue), corresponding size is reported
(right panels). d) Quantification of spheroid size evaluated as pixel log10 scale (9 fields for each
condition; CAE n=69, CTRL n=58; p<0.01) and representative pictures of spheroids derived from
pancreata of wild-type mice recovered from inflammation (CAE) or controls (CTRL) are shown.
e) Flow cytometry analysis and quantification of BrdU incorporation by epithelial spheroids
derived from wild-type mice pre-exposed or not to caerulein. DAPI is used for DNA content. Data
are shown as mean ± SD of three independent experiments. Statistical significance is assessed
with unpaired Student’s t-test (p=0.022).

This difference was further exacerbated in 2D conditions where only cells derived from
CAE-treated mice were able to grow. Replicative exhaustion in primary cultures has been linked
to senescence (133), and suppression of senescence programs during pancreatitis has been
reported (93). We thus evaluated markers of senescence, including β-Gal activity (Figure 19a),
p16 expression (Figure 19b) and histone H3 lysine 9 trimethylation (H3K9me3) (Figure 19c),
which revealed suppression of the senescence program in CAE-treated compared to control
pancreata, indicating that inflammation-induced reprograming can allow epithelial cells to evade
senescence.
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Figure 19. Epithelial cells derived from mice pre-exposed to CAE suppress senescence. a)
β-Gal staining of 2D epithelial cultures derived from pancreas of wild-type mice recovered from
inflammation (CAE) or control animals (CTRL). Scale bar =80 µm. b) Immunoblots for p16 and
vinculin on epithelial cells derived from wild-type pancreas recovered from inflammation (CAE)
or controls (CTRL). c) Immunofluorescence for H3k9me3 (red) on epithelial cultures derived
from pancreas of P48_Cre_mT/mG mice recovered from inflammation (CAE) or controls (CTRL).
mGFP (Green) indicates pancreatic origin of the cells. Cell nuclei are stained with DAPI (Blue).
Scale bar =20 µm.

In parallel, pancreatic epithelial spheroids derived from iKRAS animals were orthotopically
transplanted into inflammation-naïve recipients (250,000 cells/animal) after 5 weeks in culture,
and KRAS was induced (Figure 20).
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Figure 20. Schematics representing the experimental design for cell autonomous. Briefly,
spheroids derived from iKRAS pancreas recovered from pancreatitis (4-weeks recovery) and
control animals are orthotopically injected in recipient animals never exposed to inflammation.
Then KRAS expression is induced and mice followed for tumor development.

Mice that received cells derived from CAE-treated pancreata developed with high
penetrance aggressive tumors (Figure 21a) characterized by poorly differentiated histology and
metastasization to the liver. Although these tumors did not display classical features of
pancreatic differentiation, the expression of GFP and the exclusion of CD45 immunoreactivity
confirmed their pancreatic origin (Figure 21b).

a

b

Figure 21. Spheroids derived from mice pre-exposed to CAE cooperate with KRAS
activation to promote tumorigenesis in vivo. a) Kaplan-Meier survival of mice transplanted
with iKRAS spheroids derived from pancreas recovered from pancreatitis (caerulein, n=7) and
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control mice (untreated, n=5) after KRAS induction. b) H&E staining and immunofluorescence
for GFP (Green) and CD45 (Red) of orthotopic tumors developed from animals injected with
spheroids derived from recovered inflammation and corresponding liver metastasis. Cell nuclei
are stained with DAPI (Blue). Scale bar=200 µm or scale bar= 50 µm for main or inset images,
respectively.

Consistently, upon digestion and subcutaneous re-transplantation of isolated primary
tumor cells, the tumors acquired a more differentiated histology, as indicated by the organization
of epithelial structures and acquisition of CK19 expression (Figure 22).

Figure 22. Histology and molecular analysis of subcutaneous tumors derived from retransplantation of orthotopic spheroid-derived tumors. H&E, anti-GFP and CK19
(Green)/amylase (Red) immunostaining of subcutaneous tumors derived from re-transplantation
of orthotopic spheroid-derived tumors. Nuclei are counterstained by DAPI (Blue). Upper and
lower panel represents tumor lesions from two individual tumors, respectively. Scale bar=200
µm.
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Together, these data indicate that the inflammation-induced long-lasting epithelial
modifications that cooperate with oncogenic signaling are cell-autonomous and maintained by
pancreatic epithelial cells irrespectively of the microenvironment.

3.3 Transient inflammatory events induce sustained gene expression and chromatin
reprogramming
Next, to identify the molecular changes in epithelial cells responsible for the long-term
effect on pancreatic tumorigenesis, we performed single-cell transcriptomic analysis on WT
pancreata at different time points (1, 7, and 28 days) after treatment with CAE as well as on
PBS-treated normal animals as a control. To minimize inter-animal variability, for each time point
we pooled pancreata from three independent animals, and samples were depleted of CD45positive cells to maximize epithelial contribution especially at early time points after inflammation.
Exocrine epithelial cell populations were identified by differentiation markers (Figure 23).

a
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Figure 23. Single-cell RNA sequencing of ex-vivo pancreatic cells before (CTRL) and after
acute inflammation at different time points (day 1_D1, day 7_D7 and day 28_D28). Different
cell compartments defined (a) based on expression of top-ranking markers as shown in violin
plots (b).

Subsequent clustering analysis revealed the kinetics of transcriptomic deregulation
specifically in the acinar compartment upon inflammation (Figure 24a). Indeed, acinar cells
underwent profound transcriptomic changes immediately after inflammation (day 1). Among
them, an impairment of pancreatic digestive functions, including suppression of acinar zymogens
(such as amylase, elastase and pancreatic ribonuclease) and the concomitant upregulation of
ductal markers (such as cytokeratins 18 and 19 and Mucin1), were apparent at day 1 but
resolved by day 28 (Figure 24b). Notably, these changes are compatible with the molecular
program of acinar to ductal metaplasia (ADM) (62). Beyond these transient changes, CAEtreated acinar cells retained a modified gene transcriptional program at day 28 after inflammation
that was not observed in the ductal compartment (Figure 24a).
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Figure 24. Re-clustering of epithelial cell compartments before (CTRL) and after acute
inflammation at different time points (day 1_D1, day 7_D7 and day 28_D28). a) Epithelial
clusters (acinar and ductal compartments) as identified based on cell-type specific markers
reveal transcriptomic deregulation after inflammation mainly in acinar cells. Specifically, acinar
cells at D28 remain in a different transcriptional state with respect to control cells (left panel).
Unsupervised clustering (right panel) recognizes acinar cells at day 28 (D28) after inflammation
(orange circle) belonging to separate clusters with respect to untreated control (CTRL) (blue
circle), while ductal CTRL and D28 cells cluster together (cyan circle). b) Gene expression
dynamics of acinar and ductal markers in acinar compartment across different time points.

Ingenuity Pathway Analysis (IPA) of signature genes that defined different acinar states
uncovered the activation of programs related to cell death and survival, proliferation and cell
transformation specifically in CAE-treated animals (Figure 25a). Moreover, a set of genes
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coregulated during pancreatic embryonic development and tumorigenesis (111) was also
significantly enriched (Figure 25b). These findings support the notion that epithelial acinar cells
maintain an adaptive response to tissue damage that involves the sustained activation of multiple
gene expression programs, including embryonic programs reactivated during cancer
progression.
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Figure 25. Pathway analysis in acinar cells after inflammation. a) Diseases and biological
processes scoring in pathways analysis (IPA) associated with genes expressed in acinar cells
at D1, D7 and D28 vs CTRL. b) Development and KRAS progression signature including genes
coregulated during development and tumorigenesis is enriched at D1, D7 and D28 after acute
inflammation compared to CTRL in acinar cells.

To identify the regulatory networks responsible for this sustained transcriptional signature,
we identified DNA sequence motifs statistically over-represented in the promoters of upregulated
genes at day 28, which are recognized by distinct transcription factor families including Sp,
Kruppel-like factors (KLF), E2F and EGR (Figure 26a). To investigate whether the long-term
transcriptomic response to inflammation is associated with persistent chromatin modifications,
we mapped chromatin accessibility of pancreatic cells after inflammation. ATAC-seq analysis of
pancreata at different time points during and after the inflammatory episode revealed increased
chromatin accessibility at thousands of transcription start site (TSS)-proximal and TSS-distal
genomic regulatory elements (corresponding to promoters and putative enhancers, respectively)
in CAE-treated animals compared to controls. Both gene promoters and putative enhancers that
showed increased accessibility early during inflammation (day 1), either maintained or increased
their accessibility after full recovery of the pancreatic tissue (day 28), demonstrating that the
long-term transcriptomic response to a transient pancreatitis is accompanied by persistent
chromatin modifications in acinar cells (Figure 26b,c). Not surprisingly, functional analysis of
genes associated with the open genomic regions identified biological processes involved in
abnormal inflammation, development and cancer (Figure 26d). Moreover, motif enrichment
analysis of differentially accessible regions mapped to the same families of transcription factors
that we identified as enriched in the promoter of transcriptionally deregulated genes (Figure
26e,f). Expression of some members of these transcription factor families by acinar cells after
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inflammation, as indicated by single cell RNA-seq data, further corroborates their putative role
in sustaining the enduring response to inflammation (Figure 26g).
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Figure 26. Analysis of regulatory networks underlying persistent transcriptomic and
epigenomic changes in ex vivo acinar cells after inflammation. a) TF binding sequences
enriched in motif analysis of promoter regions of deregulated genes at D28 vs CTRL in acinar
cells. b-f) ATAC-seq of ex-vivo epithelial pancreatic cells before (CTRL) and after acute
inflammation (D1, D7 and D28). b,c) Density plots and heat maps depicting dynamics of
enriched open regions, proximal (b) or distal (c) to gene TSS, at D28 vs CTRL across different
time points. d) Pathway analysis (GREAT) of enriched chromatin open regions-associated
genes at D28 vs CTRL. e,f) Motif enrichment analysis of open chromatin regions at D28 vs CTRL
identifying overrepresented sequences recognized by transcription factor families in proximal (e)
or distal regions (f). g) Expression level of transcription factors identified via motif enrichment
analysis in single-cell RNA sequencing across different time points before and after acute
inflammation.
Taken together, these data demonstrate that, after normal pancreatic epithelial cells
histologically recover from a transient episode of inflammation, they acquire a lasting adaptive
response maintained by a persistent transcriptional and epigenetic reprogramming.

3.4 Persistent inflammation-induced reprogramming in acinar progenitor cells
Because on the one hand epithelial spheroids derived from post-CAE animals support
KRAS-mediated tumorigenesis upon orthotopic transplantation (Figure 20-22) and on the other
acinar cells are the major target of inflammation-induced reprogramming in vivo, we investigated
the relationship between epithelial spheroids and acinar cells. Epithelial spheroids derive from
Doublecortin-Like Kinase 1 (DCLK1)-positive progenitor cells (87, 134-136). To confirm that in
our experimental setting epithelial spheroids are originated from DCLK1-positive cells, we used
a mouse model in which a green fluorescent protein (ZsGreen) is expressed under the control
of the Dclk1 gene promoter (Dclk1-DTR-ZsGreen) (87) (Figure 27a), and demonstrated that the
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only cells in the pancreas able to generate spheroids were in the ZsGreen-positive fraction
(Figure 27b,c).

a
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Figure 27. DCLK1-positive cells are able to give rise to spheroids. a) Construct for the
generation of the Dclk1-DTR-ZsGreen mouse model. b) Density plots representing sorting gates
for pancreatic cells isolated from Dclk1-DTR-ZsGreen animals. c) Relative spherogenic potential
of cells sorted from single cell suspension of pancreata isolated from Dclk1-DTR-ZsGreen mice
based on their fluorescence: ZsGreen positive (DCLK1+), ZsGreen negative (DCLK1-) (n=3).
Data are shown as mean ± SD. Statistical significance is assessed by unpaired Student’s t-test.
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To further demonstrate the role of DCLK1-positive cells in maintaining spheroid cultures,
we leveraged the dyphtheria toxin (DT) receptor coexpressed alongside ZsGreen to specifically
target DCLK1-positive cells in epithelial spheroids. Exposure to DT dramatically impacted the
expansion of epithelial spheroids derived from Dclk1-DTR-ZsGreen mice but did not have any
effect on spheroids derived from wild-type animals, confirming the specificity of the results and
the critical importance of DCLK1-positive cells in spheroid maintenance (Figure 28).

Figure 28. DCLK1-positive cells are essential to spheroid maintenance. Surface area of
pancreatic spheroids derived from Dclk1-DTR-ZsGreen mice or wild-type mice treated or not
with diphtheria toxin (DT) for 5 days. Data are representative of two independent experiments.
Statistical significance is assessed by unpaired Student’s t-test. ns= non-significant.
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Because the vast majority of DCLK1-positive cells display acinar differentiation (87, 134,
137) and sustain acinar regeneration upon tissue damage in vivo (87), we functionally assessed
the ability of DCLK1-positive progenitor cells from epithelial spheroids to regenerate normal
pancreatic tissue upon damage. To this aim, we derived GFP-positive spheroids from
P48_Cre_R26-mT/mG animals and then transplanted them orthotopically into syngeneic
recipients in which pancreata were previously damaged by CAE treatment. Four weeks after
implantation, GFP-positive acinar lobules were clearly detected in the pancreata, and their
differentiation was confirmed by amylase immunostaining (Figure 29a). Interestingly, lineagetracing experiments also demonstrated that after inflammation, spheroids derived from Mist1CreERT2-mT/mG animals have an intense positivity for GFP, suggesting that the DCLK1-positive
cells at the origin of the spheroids have acinar properties (Figure 29b). Together, these findings
further corroborate previous observations that DCLK1-positive cells represent a reservoir of
pancreatic progenitor cells able to sustain both epithelial spheroids in vitro and acinar
regeneration in vivo upon tissue damage (87).
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Figure 29. DCLK1-positive cells are able to regenerate acinar cells upon tissue damage
in vivo. a) Green spheroids derived from untreated P48_Cre_mT/mG mice are orthotopically
transplanted in pancreata of WT animals 48 hours after CAE treatment. Cryosections of
pancreata from mice sacrificed at 4-week after implantation revealed GFP-positive lobules
(Green) colocalized with acinar functional marker amylase (Purple). Cell nuclei are stained with
DAPI (Blue). Scale bar =20 µm. b) Upper panels: Mist1_CreERT2_mT/mG mice are treated with
Tamoxifen to induce nuclear transfer of Cre recombinase followed by acute inflammation
induction. Pancreata are then collected and part of tissues is stained against GFP (Green) and
amylase (Red) to show efficiency of Cre recombination in acinar compartment. DAPI is used to
counterstain nuclei (Blue). White arrow indicates a non-recombined ductal and stromal structure.
Scale bar=200 µm or scale bar= 50 µm for main or inset images, respectively. Middle and bottom
panels: the other part of collected tissues was used to establish epithelial spheroids cultures.
The GFP-positivity of spheroids indicates the acinar origin.

Next, to understand the gene regulatory bases underlying reprogramming, we performed
ATAC-Seq on DCLK1-positive cells isolated from untreated or CAE-treated pancreata.
Compared to controls, DCLK1-positive cells isolated 28 days after CAE treatment were
characterized by increased chromatin accessibility at thousands of genomic regions (Figure
30a,b), and differentially accessible chromatin regions were enriched in motifs similar to those
previously identified in acinar cells ex vivo (EGR, Sp, KLF, E2F) (Figure 30c,d).
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Figure 30. Analysis of regulatory networks underlying persistent epigenomic changes in
ex vivo DCLK1-positive cells after inflammation. a-d) ATAC-seq of isolated DCLK1-positive
cells before (CTRL) and after acute inflammation (D1 and D28). a,b) Density plot and heat map
depicts dynamics of enriched open TSS proximal (a) or distal regions (b) at D28 vs CTRL across
different time points in DCLK1-positive cells. c,d) Motif analysis of enriched chromatin open
regions at D28 vs CTRL identifies over-represented sequences recognized by transcription
factor families in proximal (c) or distal regions (d).
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We also characterized epithelial spheroids derived from wild-type animals and performed
a transcriptomic analysis 9 weeks after CAE treatment or control, namely after 4 weeks of
recovery in vivo prior to 5 weekly passages ex vivo (Figure 31a). Ingenuity Pathway (IPA)
analyses of deregulated genes in epithelial spheroids derived from CAE-treated animals showed
activation of gene expression programs similar to those previously identified in acinar cells ex
vivo, which included genes controlling development, organismal injury and abnormalities, cell
movement, survival and cancer (Figure 31b). Gene Set Enrichment (GSEA) analysis
demonstrated that key PDAC tumorigenic pathways, such as KRAS and p53 as well as
functional categories related to pancreatic embryonic development and tumorigenesis (111)
were deregulated as well (Figure 31c). Moreover, ChIP-sequencing experiments on paired
spheroids from inflamed and non-inflamed pancreata using antibodies for H3K27Ac, which
detects active genomic regulatory elements, revealed a large number of persistent differences
in histone acetylation, 90% of which were located distally from gene promoters and thus
represented putative enhancers (Figure 31d). DNA sequences statistically over-represented in
the promoters of deregulated genes relative to all other RefSeq genes, as well as in the
differentially

acetylated

distal

regions

(Figure

31e),

were

characterized

by

the

overrepresentation of motifs recognized by similar families of transcription factors and the
expression of some of the TFs of these families was concordantly deregulated, suggesting a
possible causative role (Figure 31a). Of note, TF families like EGR, NK, FOX and SOX were
overlapping with those identified in DCLK1-positive cells ex vivo (Figure 30c,d), thus suggesting
that inflammation-induced reprogramming of DCLK1-positive cells is maintained in culture
conditions.
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Figure 31. Analysis of regulatory networks underlying persistent transcriptomic changes
in spheroids derived from post-CAE mice. a-c) Bulk RNA-seq on wild-type mouse pancreatic
spheroids derived from pancreas pre-exposed or not to inflammation. a) Volcano plot shows
normalized expression values of 712 differentially expressed genes in post-CAE spheroids vs.
CTRL spheroids. Blue and red colors indicate down- and up-regulated genes, respectively.
Yellow color highlights deregulated transcription factors. b) Pathway analysis (IPA) of genes
associated with diseases or biological functions enriched after inflammation vs. control. Highestranked terms are shown. c) GSEA enrichment plots showing the hallmark signature Kras
signaling and Development and Progression signature including genes coregulated during
development and carcinogenesis in pancreatic cells (111). The p53 Pathway signature, which is
enriched in down-regulated genes is also shown. Genes are ranked from left to right based on
signed p-value, with genes on the left showing significantly higher expression after inflammation
treatment. NES, Normalized enrichment score; FDR, false discovery rate. d) Bar graph shows
differential H3K27 acetylation of up-regulated and down-regulated genes in post-CAE vs. CTRL
spheroids. e) Motif enrichment analysis of TF binding sites over-representation at promoters and

80

distal regions. The over-represented families of TFs at the promoters of up-regulated (Up-P) and
down-regulated (Down-P) genes in spheroid bulk RNA-seq relative to all Refseq genes are
shown on the left. The right panel shows the over-represented TF families at the differentially
acetylated TSS-distal regions in spheroid ChIP-seq (using the FANTOM5 collection of
enhancers as background). The heat map shows the negative logarithm of the enrichment Pvalue determined by a two‐tailed Welch's t‐test.
Our data support a model in which, upon damage and tissue regeneration, the long-term
epigenomic modifications and gene expression programs acquired by DCLK1-positive cells can
be maintained in their differentiated progeny, represented by epithelial spheroids in vitro or
acinar cells in vivo.

3.5 EGR1 promotes pancreatic tumorigenesis after recovery from inflammation
DCLK1-positive cells have been reported to be the cell of origin of pancreatic cancer (87,
134, 138-140). Indeed, the intense DCLK1 staining of tumors derived from the transplantation
of epithelial spheroids is consistent with the notion that the reprogramming of pancreatic
progenitor cells may play an important role in inflammation-promoted tumorigenesis (Figure 32).

Figure 32. Left panel: Immunofluorescence for Dclk1 (Red), CD45 (Green), and DAPI (Blue) of
a tumor developed from animals injected with iKRAS epithelial spheroids derived from pancreata
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pre-exposed to inflammation. Right panel: H&E staining of the same tumor slice. Scale bar=50
μm.

To better understand how inflammation-induced reprogramming impacts oncogenic
KRAS-mediated transformation in pancreatic epithelial cells, we chose to study the biological
relevance of EGR1, a transcriptional regulator of the early growth response (EGR) gene family
involved in tissue regeneration (141) that consistently scored across all omics analyses reported
above as one of the most prominent transcription factors involved in cell reprogramming. We
first assessed EGR1 expression in pancreatitis tissue. EGR1 was highly expressed in the
nucleus of the vast majority of epithelial cells 1 day after CAE treatment, whereas it was
undetectable in control tissue. EGR1 expression persisted in pancreatitis tissue through 28 days
post-CAE treatment, though with lower intensity (Figure 33a,b). Noteworthy, EGR1 expression
was also upregulated in human samples of acute and chronic pancreatitis compared to normal
pancreas tissue, as analyzed by immunostaining (Figure 33c).
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Figure 33. EGR1 expression level is up-regulated in response to acute and chronic
inflammation. a) Immunofluorescence for EGR1 (Red) and DAPI (Blue) at different time points
(D1 and D28) after induction of inflammation in wild-type animals. Green channel (BG) is used
to highlight tissue architecture. Scale bar= 20 µm. b) Quantification of nuclear signal as pixel
log10 intensity for EGR1 in (a). Data are shown as violin plot (n=3-5 mice per group). Statistical
significance is assessed with one-way ANOVA. c) Immunofluorescence for EGR1(Red) and
DAPI (Blue) on human samples of acute and chronic pancreatic inflammation (AP and CP
respectively). Mouse samples of acute inflammation are included as positive control, and normal
human pancreata are included as negative control. Green channel (BG) is used to highlight
tissue architecture. Scale bar= 200 µm.

Next, to determine whether EGR1 is involved in pancreatic tumorigenesis in the context
of resolved inflammation, we generated Egr1-null iKRAS animals by crossing Egr1-/- mice with
TetO-LSL-KrasG12D_ROSA26-LSL-rtTA-IRES-GFP_p48-Cre animals. Although inflammatory
cell recruitment was not affected in absence of EGR1 (Figure 34a), oncogenic KRAS activation
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in matched Egr1+/+ and Egr1-/- iKRAS animals 4 weeks after inflammation revealed that Egr1+/+
iKRAS animals developed tumors with high penetrance and had dramatically shorter survival
than Egr1-/- iKRAS mice (310 days median survival in Egr1+/+ animals versus undetermined in
Egr1-/- animals; p<0.01) (Figure 34b). Consistently, when sacrificed at the endpoint of the study,
histological analysis of Egr1-/- iKRAS pancreata revealed minimal tumor burden (Figure 34c),
strongly suggesting that EGR1 is a critical player in pancreatic tumorigenesis and epithelial cell
reprogramming induced by inflammation.
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Figure 34. ERG1 ablation doesn’t affect the induction of inflammation while suppresses
epithelial memory-mediated tumorigenesis. a) Left panels: Wild-type and Egr1-null mice are
treated with caerulein to induce acute inflammation. Pancreata are then harvested and
processed for H&E and anti-CD45 (green)/Background (red)/DAPI (blue) immunostaining for
assessing undergoing inflammation. Scale bar=200 µm. Right panel: Quantification of CD45positive cells in Erg1-WT and Egr1-null mice. Each dot represents the CD45-positive cell
percentage per field. n=2 mice per group. Statistical significance is assessed with unpaired
Student’s t-test. ns= non-significant. b) Kaplan-Meier survival of Egr1-WT_iKRAS mice (n=6)
and Egr1-null_iKRAS mice (n=9) after oncogenic KRAS induction at day 28 after acute
inflammation. c) H&E staining of Egr1-WT_iKRAS mice and matched Egr1-null_iKRAS mice.
Scale bar=500 µm or scale bar= 50 µm for main or inset images, respectively.
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3.6 IL-6 mediates epithelial reprogramming during inflammatory events
To test whether epithelial reprogramming is dependent on the activity of inflammatory
cells and to identify mediators responsible for this phenotype, we cultured epithelial spheroids
derived from iKRAS pancreata with medium conditioned by CD45-positive cells isolated from
acute pancreatitis. After one week, spheroids were transferred to conventional medium and
maintained in culture for additional 4 weeks to minimize the acute effects of cytokine exposure
(Figure 35a). Spheroids exposed to CD45-conditioned medium or control spheroids were then
orthotopically transplanted into recipient mice, and KRAS expression was induced. Only mice
injected with CD45-conditioned cells developed tumors that histologically resembled those
obtained from transplantation of spheroids derived from CAE-treated pancreas. The epithelial
origin of these tumors was confirmed by GFP positivity and the mutual exclusivity of CD45
staining (Figure 35b,c).
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Figure 35. CD45-positive cells reprogram epithelial cells and promote KRAS-mediated
tumorigenesis. a) Schematics representing the experimental design. Briefly, spheroids derived
from iKRAS mice are co-cultured in presence or absence of CD45 positive cells isolated from
an acute pancreatitis. After one week, conditioned spheroids are moved to conventional medium
for other 4 weeks and then transplanted orthotopically in recipient mice and KRAS induced. b)
Kaplan-Meier survival of mice transplanted with conditioned (CD45, n=5) or not conditioned
spheroids (CTRL, n=7) after KRAS induction. c) H&E staining and immunofluorescence for GFP
and CD45 of tumors developed from animals injected with CD45 conditioned spheroids. Scale
bar=200 µm or scale bar= 50 µm for main or inset images, respectively.

88

Thus, epithelial cells undergo reprogramming in vitro in response to soluble molecules
released by the inflammatory cells that mediate inflammation-induced changes in the pancreatic
epithelium in vivo. ELISA analysis of CD45-conditioned medium revealed high levels of IL-6 and
G-CSF (Figure 36a). Because the G-CSF receptor is not expressed in pancreatic cells according
to our data set, we posited that IL-6, for which a role in PDAC progression is supported by a
large body of evidence (12, 142-145), was likely a critical mediator of epithelial reprogramming.
Exposure of spheroids to CD45-conditioned medium, as well as to recombinant Hyper-IL6, a
potent chimeric molecule able to engage gp130 trans-signaling (145), confirmed strong induction
of STAT3 phosphorylation at Tyr705 (Figure 36b). Consistently, in vivo immunostaining analysis
detected expression of IL-6-positive infiltrating cells and nuclear phospho-STAT3 signal in
virtually all acinar cells in pancreatic samples immediately after CAE-treatment (D1) (Figure
36c-e).
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Figure 36. IL-6 is one of major cytokines secreted by CD45-positive cells and mediates
STAT3 activation. a) Cytokine array of medium conditioned for 1 or 7 days with CD45,
absorbance for different antibodies is reported. Data are shown as mean  SD. b)
Immunoblotting for pSTAT3 (phosphor Tyr 705), STAT3 and Vinculin of spheroids exposed to
CD45 conditioned medium (top panel) or Hyper-IL6 200ng/ml (bottom panel) for indicated time
points. c) Immunofluorescence for IL-6 (Red), pSTAT3 (Green) and DAPI (Blue) of pancreatic
sample at day 1 after caerulein treatment showing a multitude of pSTAT3 nuclear positive cells,
including many acinar structures (yellow dashed lines), interspersed among IL6 positive cells.
Scale bar= 120 µm. d) Immunofluorescence for E-cadherin (Green), IL6 (White), pSTAT3 (Red)
and DAPI (Blue) of pancreatic sample at day 1 after caerulein treatment to show that acinar cells
are positive for nuclear pSTAT3. Scale bar=200 µm or scale bar= 50 µm for main or inset images,
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respectively. e) Immunofluorescence for CD45 (Green), IL-6 (White), pSTAT3 (Red) and DAPI
(Blue) of pancreatic sample at day 1 after caerulein treatment to show CD45-positive cells are
the major source of IL-6 (left panel). Scale bar=50 µm.

Mass cytometry immunophenotyping of CD45 cells recruited to the pancreas upon acute
CAE exposure (D1) revealed a massive infiltration of macrophages (CD68+, F4/80+, CD11+)
(Figure 37a) with only a marginal contribution of lymphoid cells (CD4, CD8, B220, NK1.1)
(Figure 37b). Furthermore, tSNE representation of immunoreactivity for IL-6 completely
overlapped with CD68, F4/80 and CD11 markers, identifying macrophages as the major source
of IL-6 production in vivo (Figure 37a).

a
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b

Figure 37. Macrophages are the main population of CD45-positive cells and the main
source of IL-6. a) CyTOF immunophenotyping of CD45 positive cells infiltrating the pancreas
during acute pancreatitis, tSNE-plots for CD68, CD11, F4/80 and IL-6 are reported. b) CyTOF
immunophenotyping of CD45 positive cells infiltrating the pancreas during acute pancreatitis,
tSNE-plots for CD4, CD8, B220 and NK1.1 are reported.

Next, we measured the expression of the key transcription factor EGR1 by immunoblot
analysis that revealed its strong and sustained upregulation after exposure of spheroids to
Hyper-IL6 for 24 hours (Figure 38a). To determine the role of IL-6 in EGR1 expression in vivo,
we analyzed pancreata from Il6-null mice. As anticipated, even though inflammatory cell
recruitment was not affected (Figure 38b), EGR1 expression was markedly impaired in Il6-null
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pancreas tissue after CAE treatment compared with Il6-proficient controls (Figure 38c,d). These
in vitro and in vivo findings demonstrate that IL-6 is a key mediator of the inflammation-induced
reprogramming of epithelial cells.

a

b
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c
d

Figure 38. IL-6 mediates epithelial reprogramming during inflammation. a) Immunoblotting
for pSTAT3 (phosphor Tyr 705), STAT3, EGR1 and Vinculin of spheroids exposed to Hyper-IL6
200ng/ml for 24 hours and then sampled at indicated time points after Hyper-IL6 wash-out. b)
Left panels: Immunofluorescence for CD45 (Green), background (Red) and DAPI (Blue) of WT
and Il6-null pancreata at D1 after inflammation. Scale bar =200 µm. Right panel: Quantification
of CD45-positive cells in WT and Il6-null mice. Dots represent percentages of CD45-posotive
cells per field, n=3 mice per group. Statistical significance is assessed with unpaired Student’s
t-test. ns= non-significant. c) Pancreata from wild-type or Il6-null mice at day 1 after acute
inflammation are harvested and immunostained for EGR1 (Red). Cell nuclei are counterstained
with DAPI (Blue). Scale bar =200 µm. d) Quantification of nuclear signal as pixel log10 intensity
for EGR1 as in (c). Data are shown as violin plot (n=3 mice per group). Statistical significance is
assessed by unpaired Student’s t-test.
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3.7 Acinar to ductal metaplasia is facilitated by epithelial memory to limit tissue damage
As any adaptive process, epithelial memory of previous inflammation should improve
organismal fitness. Because of the transcriptional reprogramming of the acinar compartment in
vivo, one possibility is that such memory provides a defense mechanism in case of recurring
inflammatory events that are common in the pancreas and that would otherwise result in the
repeated release of pancreatic enzymes and cumulative tissue damage. To understand how a
discrete inflammatory episode can influence subsequent inflammatory events, we rechallenged
wild type animals that had recovered from CAE-induced acute pancreatitis with a second
inflammatory trigger (Figure 39a). Early evaluation of pancreatic enzymes (Figure 39b) as well
as lactate dehydrogenase (LDH, a marker of cell lysis) (Figure 39c) in the blood of wild-type
mice 24h after pancreatitis induction revealed that both enzymes in the rechallenged group were
comparable to control animals. This suggests that a sustained adaptive response triggered by
the first inflammatory event attenuated pancreatic damage induced by a second acute
inflammation. Indeed, at the histological level, only the pancreata of animals receiving the first
inflammatory trigger had extensive acinar damage (Figure 39d), as further confirmed by
immunostaining for cleaved caspase 3 (CC3) (Figure 39e).

b

c

a
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e

Figure 39. Pre-exposure to inflammation attenuates tissue damage caused by the
subsequent challenge. a) Schematics representing the experimental design. To investigate the

97

role of epithelial memory, wild type or iKRAS mice were rechallenged with a second acute
pancreatitis after the complete recovery from a previous one. Pharmacologic modulation of ADM
or KRAS induction was obtained by treating mice with EGF, MEK inhibitor or doxycycline (KRAS
induction) 2 days before and during the administration of caerulein. b,c) Levels of amylase (b)
and LDH (c) detected in the peripheral blood at 24hs after the induction of acute pancreatitis (D0)
in WT mice; untreated mice (CTRL, n=3), mice without memory after a single inflammation
(Single, n=3), mice with memory after rechallenging (Rechallenged, n=3). Data are shown as
mean  SD. Statistical significance is assessed with one-way ANOVA. d) H&E staining of wild
type pancreata with or without memory (Rechallenged or Single Inflammation respectively) at
24hs after induction of acute pancreatitis (D0). Scale bar=100 µm. e) Immunofluorescence for
cleaved caspase 3 (CC3-Red) and DAPI (Blue) of pancreata at 24hs after the induction of acute
pancreatitis (D0) in WT mice with (Rechallenge) or without memory (Single Inflammation). Green
channel (BG), although unstained, has been acquired and used to highlight tissue architecture
and vessel. Scale bar= 200 µm or Scale bar=100 µm for main or inset images, respectively.
Quantification of cleaved caspase-3 level in single inflammation and rechallenged group is
shown (right panel). Each dot represents CC3-positive area per field. n=4 mice per group.
Statistical significance is assessed by unpaired Student’s t-test.

Unexpectedly, the pancreata of rechallenged animals responded to the second
inflammatory event by undergoing an extensive acinar-to-ductal metaplasia (ADM), as indicated
by the increased CK19/Amylase staining ratio and the associated morphological changes
(Figure 40a). Such ADM was much more pervasive than that observed in animals exposed to a
single challenge and completely manifested within 48 hours post-CAE administration. In spite of
its pervasive character, ADM was completely resolved by day 7 post-CAE administration, as
demonstrated by the full recovery of normal pancreatic tissue (Figure 40b).
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Figure 40. Rapid and massive acinar-to-ductal metaplasia (ADM) is induced during
rechallenging. a) Immunofluorescence for CK19 (Green), amylase (Red) and DAPI (Blue) at
24hs (Day 1) after a 2-day inflammation in wild-type mice (Untreated) or mice with (Rechallenge)
or without memory (Single Inflammation). Scale bar= 200 µm or scale bar= 50 µm for main and
inset images, respectively. Quantification of CK19/Amy ratio in the same experimental groups is
shown in the lower panel. Each dot represents CK19/Amy ratio per field. n=3 mice per group.
Data are shown as mean  SD. Statistical significance is assessed with one-way ANOVA. b)
Immunofluorescence for cytokeratin-19 (KRT19, Green), amylase (AMY2A, Red) and DAPI
(Blue) of wild type pancreata with or without memory (Rechallenged or Single Inflammation,
respectively) before and after 2-day caerulein treatment (Day 1 and Day 7). Scale bar= 200 µm.

Thus, the sustained adaptive response triggered in the pancreatic epithelium by an acute
inflammatory event resulted in a markedly attenuated response to subsequent inflammatory
episodes. Such decreased tissue damage was accompanied by the rapid dedifferentiation of
acinar cells that lasted for the length of the stimulus, and from which the tissue promptly and
completely recovered after the inflammation. To explore the hypothesis that ADM is a physiologic,
fast and reversible adaptation mediated by epithelial memory that limits the detrimental effects
of repeated pancreatitis, we evaluated the effects of pharmacological modulation of ADM in
iKRAS animals subjected to repeated inflammation. Because ADM is mediated by the activation
of MAPK signaling (60, 146, 147), we counteracted or promoted ADM formation with a highly
selective clinical MEK1/2 inhibitor (trametinib) or EGF (a MAPK activator), respectively (Figure
39a). Mice that were pretreated with EGF before and during CAE rechallenge had a further
increase of ADM formation with respect to control mice rechallenged with CAE alone (~3-fold
relative area increase, p<0.01) with decreased tissue damage as indicated by CC3
immunostaining (~8-fold, p<0.01) (Figure 41a-d) and enzyme levels in peripheral blood (Figure
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41e). Conversely, animals pre-treated with trametinib developed minimal ADM accompanied by
a very severe pancreatitis with massive apoptosis and extensive acinar loss (Figure 41a-e).
Taken together, these data support a model in which sustained epithelial adaptation in response
to inflammation involves the facilitation of ADM. By blocking the production of acinar zymogens
during sequential inflammatory events, ADM provides strong protection from tissue damage.
Because ADM has protective effects against pancreatic damage, we posited that selection of
mutations that confer constitutive activation of MAPK signaling, such as mutations of KRAS, may
be beneficial and thus be under strong positive evolutionary pressure. Toward an initial
evaluation of this possibility, we studied the impact of inducing mutant KRAS prior to a second
inflammatory event. Indeed, in animals with epithelial memory, constitutive activation of KRAS
signaling prior to the second CAE exposure resulted in massive ADM and virtually no tissue
damage (Figure 41b-f).

a

101

b

102

c

d

e

f

Figure 41. ADM as a physiological and reversible adaptation to limit tissue damage. a)
Representative H&E staining of iKRAS pancreata at 28 days from resolved inflammation after
pharmacological treatment with EGF or MEK inhibitor as well as untreated control. Scale bar=50
µm. b) Upper panels: H&E staining of pancreata of iKRAS mice at day 1 after rechallenging in
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presence/absence of pharmacological treatment with EGF, MEK inhibitor or induction of KRAS.
Scale bar=100 µm. Middle panel: Immunofluorescence for CK19 (Green), amylase (Red) and
DAPI (Blue) at 24hs (Day 1) after rechallenging in presence/absence of pharmacological
treatment with EGF, MEK inhibitor or induction of KRAS. Scale bar=200 µm or scale bar= 50 µm
for main or inset images, respectively. Lower panels: Damage evaluation in iKRAS-rechallenged
mice, immunofluorescence for cleaved caspase 3 (CC3-Red) and DAPI (Blue) at 24hs (Day 1)
after rechallenging in presence/absence of pharmacological treatment with EGF, MEK inhibitor
or induction of KRAS. Green channel (BG), although unstained, has been acquired and used to
highlight tissue architecture and vessel. Scale bar=200 µm or scale bar= 50 µm for main or inset
images, respectively. c) ADM level in (b) middle panels is quantified as CK19/Amy ratio. Each
dot represents CK19/Amy ratio per field. n=3 mice per group. Data are shown as mean  SD.
Statistical significance is assessed with one-way ANOVA. d) Pancreatic damage quantification
evaluated as cleaved caspase 3 positive area (Log 10 scale), same setting as in (b) lower panels.
Each dot represents CC3-positive area per field. n=3 mice per group. Data are shown as mean
 SD. Statistical significance is assessed with one-way ANOVA. e) Levels of LDH detected in
the peripheral blood at 24hs (Day 1) after rechallenging in presence/absence of pharmacological
treatment with EGF, MEK inhibitor or induction of KRAS (n=3 for each group). Data are shown
as mean  SD. Statistical significance is assessed with one-way ANOVA. f) Wild-type mice and
iKRAS mice without KRAS induction (KRAS off) are treated with caerulein to induce acute
inflammation. A second caerulein challenge (rechallenging) is given at D28 after the first
challenge to induce ADM formation. iKRAS mice with KRAS induction (KRAS on) during
rechallenging are included as a positive control. Pancreata are harvested and stained with antiamylase (red) and CK19 (green) antibodies. Cell nuclei are stained with DAPI (blue). ADM level
is quantified by the ratio between amylase and CK19. n=3 mice per group. Statistical significance
is assessed by one-way ANOVA. ns= non-significant. Scale bar=200 µm or scale bar= 50 µm
for main or inset images, respectively.
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Chapter 4. Discussion and future directions
Inflammation evolved as a nonspecific damage response that coordinates the activation
of innate immunity with tissue repair to accelerate parenchymal regeneration and the restoration
of tissue integrity after injury (12, 148). While the cellular and molecular events that lead to the
activation of the immune compartment during an inflammatory response have been extensively
characterized, the short- and long-term effects of inflammation on parenchymal cells are much
less understood. Although quiescent stem cells in tissues can be activated by a variety of
damage signals during injury adaptations of the stem cell compartment in response to
inflammation-inducing damage have only recently been reported. Indeed, two seminal papers
have shown that the regenerative capability of stem cells is strongly increased following tissue
damage, suggesting the existence of a cellular memory-like phenotype, namely a sustained
adaptive response, in the stem cell compartment (70, 149), adaptations of the stem cell
compartment in response to inflammation-inducing damage have only recently been reported.
Indeed, two seminal papers have shown that the regenerative capability of stem cells is strongly
increased following tissue damage, suggesting the existence of a cellular memory-like
phenotype, namely a sustained adaptive response, in the stem cell compartment
In the specific case of the pancreas, the production of highly active and potentially tissuedestructive enzymes by acinar cells brings about a high risk of widespread organismal damage
in case of inflammation-induced acinar damage. By using a model of acute pancreatitis, we
demonstrated that a short inflammatory episode has a long-lasting effect on pancreatic epithelial
cells that results in significant protection of tissue integrity. Specifically, upon a second discrete
inflammatory event, acinar cells promptly underwent massive acinar-to-ductal metaplasia (ADM),
a transdifferentiation or dedifferentiation process that leads to the accumulation of progenitorlike cells with ductal features that are unable to secrete zymogens (62, 134). This fast and
reversible adaptation appears to be of critical importance in light of the pathogenesis of
pancreatitis, wherein zymogens, normally excreted in the duodenum, are prematurely activated
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within the pancreatic tissue as well as released in the circulation. During repeated inflammatory
events, the proclivity of adapted acinar cells to activate the ADM program may serve two critical
functions: 1) to shut down zymogen production that would otherwise fuel further damage, and 2)
to prompt acinar cells to acquire ductal features that render them more resistant to the
detrimental effects of enzymatic activation. The emerging concept of ADM as a physiologic
process that limits pancreatic damage during pancreatitis (150) is further supported by the
sustained adaptation described here. Indeed, by facilitating a rapid acquisition of ADM, epithelial
memory promptly counteracts damage, reduces inflammation, and promotes tissue regeneration.
Because ADM is mediated by the activation of MAPKs (60, 146, 147), stabilization of the
metaplastic phenotype through constitutive signaling plausibly exerts an important protective
role to limit tissue damage, making activating mutations of KRAS beneficial events in the context
of recurrent pancreatitis. It is thus not surprising that activating mutations of KRAS are found in
~25-37% of chronic pancreatitis cases, as well as in the vast majority of early pancreatic
intraepithelial neoplasia (PanIN) lesions (82, 151).
Taken together, this study, consistent with recent observations in other organ contexts
(152), unmasks a previously unappreciated role of oncogenic mutations in preserving tissue
homeostasis during repeated damage. Such a positive effect, independent from its eventual
contribution to tumorigenesis, can explain why some oncogenic mutations, such as KRAS in
pancreas, represent a nearly universal event in specific disease contexts. In light of these
observations, we speculate that the pharmacological induction of ADM with MAPK agonists,
such as TGFα and EGF, might ameliorate pancreatitis by protecting acinar cells from tissue
damage while also reducing the positive pressure to mutate KRAS. This therapeutic strategy
may thus hinder the progression of pancreatitis to PDAC.

Primary culture has been reported to be a useful approach to expand cells within an
environment which closely mimics the in vivo physiological condition while limiting the
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accumulation of new genetic perturbations in vitro (153). Pancreatic primary culture primarily
relies on organoid culture (153, 154). Although other approaches have been developed, like
spheroid cyst culture (104, 155), all culture methods use similar ways to either isolate pancreatic
ducts or ductal cells as the source of primary cells before being followed up by 3D cell culture.
The reason why ductal cells have been selected as the target population for primary culture may
be due to the fact that acini have been repeatedly isolated but have failed to be cultured in vitro.
Indeed, only cells associated with ductal structures seem to bud and grow in vitro as organoids.
Further, as pancreatic cancer has long been postulated to derive from ductal cells, the culture
of ductal cells could be used as a surrogate system to study pancreatic cancer.
Mouse pancreatic primary culture derived from ductal cells can propagate indefinitely and
display ductal structures when transplanted orthotopically in syngeneic mice (153). However,
this does not exclude the possibility that other types of cells have the ability to maintain primary
culture and generate functional units in vivo. To avoid any bias due to cell selection, we used a
protocol that enabled the capture of every epithelial progenitor cell endowed with spherogenic
potential. To this purpose, upon pancreata digestion, we plated all epithelial cells instead of
performing the selective enrichment of large ductal structures, which has been done by other
groups to derive pancreatic spheroids. When we performed orthotopic transplantation of
spheroids in vivo, we found that spheroid cells are able to differentiate to functional acinar cells
upon tissue damage. Moreover, we observed that spheroids derived from the pancreas right
after acute inflammation possess acinar properties. These data suggest that primary culture can
be sustained by different cell populations—a finding which needs to be taken into consideration
when using primary culture as an experimental model.

In the current study, we demonstrated that cooperation between oncogenic KRAS
activation and the effect of resolved inflammation on pancreatic epithelial cells to promote
pancreatic tumorigenesis can last for at least three months. Further, we orthotopically
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transplanted pancreatic spheroids derived from animals pre-exposed to inflammation in recipient
mice never exposed to inflammation, and found that these spheroids were able to develop
tumors upon oncogenic KRAS activation. This finding indicates that the effects of resolved
inflammation are maintained at the cell autonomous level. Because of the cell autonomous
nature and the fact that this process can last for a long period of time, we have described the
effect of resolved inflammation as epithelial memory.
The tumor is a complex ecosystem consisting of cancer cells as well as other cell types
including immune cells and stromal cells. The effects of stromal and immune cells, as well as
those of other microenvironmental components, on cancer cells and tumor progression have
been widely studied (156). Although our data showed that the effect of epithelial memory on
tumor progression is cell autonomous, this finding does not mean that the development of tumors
exclude the role of the microenvironment. Instead, we believe that cells with epithelial memory,
upon transplantation and oncogenic KRAS induction, re-organize the microenvironment of
recipient pancreata through crosstalk between epithelial cells, immune cells and stromal cells to
promote tumor progression. This hypothesis can be easily addressed by comparing the
microenvironment of pancreas transplanted with cells with or without memory at different time
point via single-cell sequencing or CyTOF analysis.
Additionally, to exhaustively investigate whether the effect of resolved inflammation is cell
autonomous, we can induce acute pancreatitis in the recipient mice, orthotopically transplant
iKRAS spheroids derived from mice never exposed to inflammation, and activate KRAS. Based
on the phenotype of transplanted pancreas and our current data, we can conclude whether the
effects of resolved inflammation are cell autonomous, microenvironmental, or both.

The existence of epithelial memory is manifested via two phenotypes in pancreas. One is
the accelerated tumorigenesis resulting from the activation of KRAS in animals pre-exposed to
a transient inflammatory event, and the second is the rapid formation of ADM to limit tissue
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damage during repeated inflammatory events. While cells of origin of pancreatic tumors have
not been definitively identified, data collected from tumors derived from epithelial spheroids
orthotopically transplanted in recipient mice indicate that at least some cells that constitute the
spheroids possess the ability to sustain tumorigenesis. We demonstrated that DCLK1-positive
cells (pancreatic progenitor cells) can give rise to spheroids and are essential for their
maintenance. We also showed that DCLK1-positive cells acquire persistent epigenomic
modifications after exposure to acute inflammation. Of note, when we profiled epithelial
spheroids derived from mice pre-exposed to inflammation, we found that a part of the long-term
transcriptional and epigenetic alterations that epithelial cells acquire in vivo is still maintained in
vitro. Our data suggest that DCLK1-positive cells represent one of the cell populations that gets
reprogrammed after inflammation and may give rise to pancreatic tumors. This model is also
consistent with other studies reporting that stem cells possess the ability to undergo chromatin
remodeling and maintain chromatin accessibility after the inflammatory event (70).
Terminal-differentiated pancreatic acinar cells undergo ADM in response to different
stimuli, including pancreatitis. Single-cell RNA-seq analysis showed that, after inflammation, only
acinar cells acquire persistent transcriptomic changes while ductal cells do not undergo any
major transcriptional reprogramming. Moreover, ATAC-seq analysis demonstrated that
pancreatic differentiated acinar cells maintain epigenomic changes after acute inflammation,
which is consistent to transcriptomic profiling. Since we demonstrated that DCLK1-positive cells
are able to differentiate to acinar cells upon tissue damage, we reasoned that the epithelial
memory acquired by acinar cells was actually inherited from DCLK1-positive cells. Indeed, many
transcription factors involved in the regulatory networks that sustain epithelial memory are in
common between acinar and DCLK1-positive cells. This suggests that, in response to pancreatic
tissue damage, epithelial memory acquired by the DCLK1-positive compartment can be
transmitted to its more differentiated progeny during regeneration. When the tissues encounter
a subsequent inflammatory event, the differentiated acinar cells with epithelial memory can
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rapidly undergo ADM, which suppresses the release of digestive enzymes and thus limits the
damage caused by tissue self-destruction and inflammation. However, it’s also possible that the
differentiated acinar cells themselves have the ability to autonomously undergo reprogramming
during inflammation to be better adapted to future inflammatory events.
Additional studies are needed to understand the process of cell reprogramming as well
as to identify the cell type(s) that this adaptive process targets. One can consider to use a
genetically engineered mouse model (GEMM) in which a reporter gene is under the Dclk1
promoter. For example, mice with conditional Cre expression driven by Dclk1 (Dclk1-CreERT2)
and with green fluorescent protein (GFP) expression controlled by a loxP-flanked stop codon
(loxP-Stop-loxP-GFP) can be treated with tamoxifen to activate Cre activity and convert DCLK1positive cells to GFP-positive cells. After the induction of acute inflammation, both GFP-positive
and GFP-negative acinar cells will be harvested and profiled. Comparison of these two
populations will reveal whether pre-existing acinar cells (GFP-negative) or newly regenerated
acinar cells (GFP-positive since they are the progeny of recombined DCLK1-positive progenitor
cells) are the recipient of epithelial memory in vivo.

In the current study, we demonstrated that pancreatic tumors could arise from pancreatic
progenitor cells (DCLK1-positive cells). Interestingly, through the use of the Mist1CreERT2_LSL-Kras_mTmGL/L mouse model, in which Mist1-driven Cre activates the expression
of GFP and oncogenic KRAS specifically in acinar cells upon tamoxifen administration, we also
found the development of PDAC precursor lesions in the GFP-positive compartment after 22
weeks from tamoxifen treatment (data not shown). This suggests that acinar cells could be the
cells of origin of pancreatic cancer.
The discrepancy of the results doesn’t mean they are mutually exclusive, in fact, the cells
of PDAC origin could be the same population with both progenitor and acinar properties, as
being reported previously (87). To address our hypothesis, we will generate a mouse model
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with Dclk1-CreERT2, LSL-Kras-2A-Tomato, as well as with inverted Mist1-Flp and Frt-Stop-FrtGFP alleles to perform tumor lineage-tracing experiments (Figure 42). Once the mice are treated
with tamoxifen, Cre recombination in DCLK1-positive cells will activate the expression of
oncogenic KRAS and Tomato fluorescent protein. Meanwhile, the inverted Mist1-Flp allele
flanked by loxP sites in opposite orientations will be reversed, which enables the expression of
flippase (Flp) in cells positive for the acinar marker Mist1. The expression of Flp can then remove
the stop codon flanked by flippase recognition target (FRT) sites and induce the expression of GFP.
With this lineage-tracing model, in which only DCKL1-positive cells of acinar origin co-express GFP
and Tomato, we will understand whether cells that are able to give rise to pancreatic tumors are
restricted to the DCLK1-positive cells with acinar markers. This lineage-tracing model shall inform on
the origin of PDAC and provide new insights into PDAC initiation and progression.

Figure 42. Dclk1-Mist1-KrasG12D lineage-tracing model for PDAC cells of origin.

We identified EGR1, a transcription factor that participates in a variety of physiological
processes including apoptosis, proliferation, and differentiation, as a key regulator for epithelial
memory based on 4 omics analysis (ex vivo acinar cells single-cell RNA-seq, ex vivo pancreatic
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cells ATAC-seq, ex vivo DCLK1-positive cells ATAC-seq, and in vitro spheroid bulk RNA-seq).
Our data show that EGR1 is upregulated during inflammation and potentially binds to the
promoter of deregulated genes and open chromatin regions after inflammation. Moreover,
ablation of EGR1 in vivo significantly inhibits epithelial memory-promoted tumorigenesis. To
exclude the possibility that EGR1 itself is essential for tumorigenesis independent of epithelial
memory, we plan to ablate EGR1 in the canonical KPC mouse model to demonstrate whether
EGR1 ablation affects pancreatic cancer initiation and progression in KPC model. To further
confirm our findings of epithelial memory in terms of differential chromatin accessible regions,
we will perform ATAC-seq analysis in the setting of inflammatory rechallenge to see if differential
open chromatin regions at Day 28 after the first inflammation rapidly gain accessibility upon the
second inflammatory event. Moreover, we could induce acute inflammation in Erg1-null and
Egr1-WT mice and investigate whether EGR1 ablation influences chromatin accessibility at
identified regions at Day 28 after inflammation compared to untreated controls. These
experiments will shed more light on inflammation-induced epithelial memory and the role that
ERG1 exerts in epithelial memory.
CD45-positive cells are the main effectors during inflammation. We showed that coculturing with CD45-positive cells is able to reprogram pancreatic primary epithelial cells in vitro
and promote tumorigenesis in vivo after oncogenic KRAS activation. We then identified IL-6, a
major pro-inflammatory cytokine secreted by CD45-positive cells, primarily macrophages, as a
potential upstream mediator for the acquisition of epithelial memory. Indeed, the engagement of
IL-6 on pancreatic primary cells leads to the activation of STAT3 and the subsequent induction
of EGR1. Furthermore, while in vivo CD45-positive cell infiltration is not affected in the context
of IL-6 ablation, the absence of IL-6 largely decreases the induction of EGR1 during acute
inflammation. This finding suggests that IL-6 is critical for the acquisition of epithelial memory in
vivo. To further verify the role of IL-6 in epithelial memory, we can directly assess the extent of
ADM formation in wild-type and IL-6 null animals in a setting of inflammation rechallenge.
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Specifically, we expect that the ablation of IL-6 should drastically diminish the rapid and massive
acquisition of metaplastic lesions.
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